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ABSTRACT 
MODULATING NANOPARTICLE-PROTEIN INTERACTIONS THROUGH 
COVALENT OR NONCOVALENT APPROACH FOR BIOMEDICAL 
APPLICATIONS  
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M.A., SHANGHAI JIAO TONG UNIVERSITY 
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Discoveries at the interface of chemistry, biology, and materials science has emerged as a 
powerful route to impact life science in this century. My research in the Thayumanavan 
group is focused on problems at this interface. A common theme of all the six projects is 
the use of modern synthetic organic chemistry to build interesting, novel macromolecules 
which are chemically rich, to study the molecular self-assembly behavior in solution and 
then translate to solve problems in biomedical area. By addressing the design challenge to 
prepare novel amphiphiles with desired functional groups, controlled molecular weight and 
the ability to respond to a broad range of stimuli, especially protein and enzyme, we have 
achieved the following aims that showed great potential for biomedical applications such 
as sensing, imaging and drug delivery: a) we have systematically studied the molecular 
weight effects and hydrophilic-hydrophobic balance effects on enzyme induced 
supramolecular disassembly, which could provide tunability over covalent and non-
covalent guest molecules release kinetics. b) Other than single stimuli-responsive system, 
we outlined a simple and new strategy was outlined for amphiphilic nanoassemblies to 
viii 
respond to a combination of intrinsic trigger protein and extrinsic trigger light in the logic 
gated fashion. c) Considering biomedical applications based on these nanoassemblies, we 
then try to solve the most critical step for nanomedicine, which is specific targeting. Unlike 
common strategies relying on complementary ligands, we showed a cellular AND gate for 
highly selective cell accumulation by covalently masking and unmasking ligands on block 
copolymer based nanogels, such an ability will facilitate tumor imaging and diagnostics; d) 
We then showed a self-immolative nanogel platform to deliver hydrophobic drugs, with 
accessible functional group present on the surface, this nanogel can be easily functionalized 
with various receptors for targeted delivery into cytosol and subcellular organelles; e) We 
designed a novel supramolecular approach that selectively transports water-soluble 
globular proteins from an aqueous phase to the water-pool of a reverse micelle in an apolar 
organic phase. Proteins can maintain functions after crossing an incompatible solvent 
interface, which opens new possibilities for application of supramolecular assemblies in 
sensing, diagnostics and catalysis. f) following these findings, we designed an enzyme 
nanoreactor for catalysis in apolar solvent and introduce crosslinks in the molecular 
assemblies, we will further try to control substrate permeability into the assembly to 
engineer unnatural selectivity in enzymes. 
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1 
CHAPTER 1 
 INTRODUCTION 
1.1 Supramolecular assembly  
Amphiphilic molecules, ranging from small molecule surfactants, oligomers, dendrimers 
to higher molecular weight polymers, could aggregate in a self-organized fashion.1-5 The 
self-assembled aggregates maintain an equilibrium with respecting monomers, could 
generate various morphologies such as micelles, vesicles, fibers and helical shape based on 
the molecule packing parameters (Figure 1.1).  
 
 
Figure 1.1 Self-assembled structures from amphiphilic molecules. Reproduced from ref. 3 
 
 
The self-assembly process is usually driven by non-covalent interactions such as van der 
waals forces, pi-pi interactions, hydrogen-bonding, electrostatic interactions and 
hydrophobic effects.6-7 These reversible interactions make self-assembly a dynamic 
process  in response to environment cues. But amphiphiles must reach a certain 
concentration to form assemblies, which is called its critical aggregation concentration 
(CAC). Small molecular weight surfactants usually possess a relative high CAC value 
compare with higher molecular weight amphiphiles, due to its fast exchange with 
  
 
2 
corresponding aggregates. Surfactants have been often used as detergents, emulsifiers, 
foaming and anti-foaming agents. Self-assembled structures from higher molecular weight 
amphiphiles ten to be more thermodynamically stable, which could find interesting 
applications in a variety of areas such as sensing, drug delivery and diagnostics. Since 
amphiphilic molecules contain two distinctly different components: hydrophilic moiety 
and hydrophobic moiety, when they assemble in aqueous phase, the hydrophilic functional 
groups would present on the surface of the assemblies to form the primary interface with 
the solvent. Variations of the functional groups that would further induce changes in 
hydrophobic-hydrophilic balance of the assemblies could provide a lot of interesting 
applications. This thesis here will introduce different type of assemblies formed by 
dendrimers, oligomers and also polymers and potential applications. 
1.2 Protein responsive supramolecular assemblies 
Stimuli-responsive systems, which could respond to a certain environment stimulus, have 
raised particular interest in the past few decades because they can easily find use in a very 
broad range of applications.8-10 For example, one could design supramolecular assemblies 
that is sensitive to pH change and yield a response in the form of guest molecule release. 
Various types of stimuli have been used as a trigger to induce the response of assemblies 
(Figure 1.2). In the context of biology, the triggers can be classified into two categories: 
extrinsic stimuli and intrinsic stimuli. Extrinsic stimuli include light, magnetic field, 
ultrasound, electric field and mechanical forces; intrinsic stimuli include pH, redox, 
temperature, nucleic acids, sugars, enzyme and protein. Current studies have reported a lot 
of advances in secondary imbalances such as pH, redox and temperature, however those 
are just secondary imbalances in biology. In the prospective of biomedicine, we are more 
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interested in developing protein or enzyme sensitive assemblies, because most of the 
pathological imbalances are directly caused by aberrant protein activity. 
 
Figure 1.2 Various types of stimuli triggers. Reproduced from ref. 11. Copyright © 2014 
Elsevier B.V. All rights reserved. 
 
First, we targeted assemblies that are capable of responding to enzyme. Past few decades 
have witnessed considerable progress in the field of enzyme-responsive assemblies.12-17 
Typically these assemblies possess enzyme-reactive moieties in the form of labile linkages 
among the main or side chains of the molecular scaffold. Therefore, enzyme-catalyzed 
reactions induced chemical structural changes of the synthetic molecules could further lead 
to morphological transitions of these assemblies. We have shown several dendrimer 
amphiphiles that could undergo enzyme-induced disassembly by installing enzyme-
responsive units onto the hydrophobic core of the micelle-like assemblies 15, we envisaged 
that the equilibrium between the unimeric state and the aggregate state must be involved 
in this process (Figure 1.3). We have been interested in investigating how the reaction 
kinetics and the ensuing change in the host-guest characteristics would be affected by 
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tuning unimer-aggregate equilibrium to alter the assemblies’ accessibility to the enzyme. 
Moreover, we were interested in identifying as to how structural changes in host assemblies, 
induced by an enzyme, would affect rate of disassembly and kinetics of guest molecule 
release.  
 
 
Figure 1.3 Schematic representation of enzyme-induced disassembly of dendritic micelles 
 
 
While the enzyme-sensitive disassembly is dictated by a covalent and irreversible 
modification of the assemblies, supramolecular disassembly based on noncovalent 
interactions is also of great interest and a challenge, since a lot of disease-relevant proteins 
do not have known enzymatic activity. We envisaged that non-covalent binding between a 
ligand and protein could be utilized to develop a non-enzymatic protein responsive 
assembly. We designed a ligand-bearing amphiphilic dendron that formed stable 
assemblies but disassembled upon binding the target protein (Figure 5).18 We hypothesized  
that the HLB of an assembly was significantly different from that of the protein−assembly 
complex, because the protein was rather large in molecular weight and was much more 
hydrophilic compared to the amphiphile. We actually found that ligand bearing assemblies 
were disrupted only by a target protein but not by other non-complementary proteins, 
indicated by the size decrease and guest molecule release. 
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Figure 1.4 (a) Illustration of protein-induced disassembly; protein binds to the ligand 
present on the dendron’s hydrophilic face, leading to the formation of an overall 
hydrophilic protein−dendron complex and micelle disassembly. (b) Structure of G2 
dendron with enzyme responsive functional group 
  
1.3 AND gated supramolecular disassembly 
In addition to assemblies that can be triggered by a single stimulus, recent interests have 
been attracted by multiple stimuli-responsive systems, because they can provide enhanced 
selectivity in stimuli-responsiveness, which is critical in targeted delivery.10 In engineering 
the combinations of these two triggers, we were inspired by the molecular logic gates 
proposed and studied over past couple of decades.19-23 While there have been many reports 
on molecular logic gates involving small molecules, such gated strategies in nanoscale 
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assemblies are relatively limited, especially the ‘AND gate’. We have introduced a dual 
protein stimuli-responsive AND gate design to amphiphilic dendrimers, where the system 
only responded to the concurrent presence of two different proteins (Figure 1.5).24  A 
dendron molecule was designed containing an enzyme sensitive coumarin ester as the 
hydrophobic moiety and a protein-specific 2,4-DNP ligand as part of the hydrophilic PEG 
moiety. The release of the fluorescent umbelliferone from the coumarin ester cleavage due 
to the dual protein triggers was indeed found to be 26 times faster than that due to the 
enzyme alone.  
 
Figure 1.5 (a) Illustration of dual responsive system. (b) Enzyme induced change in the 
amphiphilic dendron accompanied by fluorophore release.24 
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1.4 Stimuli-responsive assemblies for targeting and drug delivery 
Traditional routes of drug administration include systemic delivery, oral delivery and local 
injection, none of these methods are satisfying because they usually generate side effects 
due to drug degradation during circulation,  undergo harsh environment and cause damage 
to surrounding tissues. To overcome these shortcomings, drug delivery system that can 
deliver the required dose of drugs to the specific disease site come into the stage. Our group 
has outlined the figure of merits for an ideal drug delivery system 25: (a) it has to be 
nontoxic to human body; (b) it should be able to provide stable guest molecule 
encapsulation; (c) the delivery system could respond to certain stimuli so that the drug 
molecules can be released in presence of the trigger; (d) the carrier should be able to 
selectively accumulate at the disease site through either passive targeting or active 
targeting. 
 
Figure 1.6 Figure of merits for an ideal drug delivery vehicle.25 
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Among these features, targeting specific disease cells is critical for a drug delivery system 
to be applicable in-vivo. It has been suggested that drug carriers with a size range of 10-
200 nm may exhibit preferential accumulation in the context of tumors, mainly due to the 
extravasation of drug carriers into solid tumor tissues and prevent lymphatic drainage, the 
so-called enhanced permeation and retention (EPR) effect.26-27 Drug carrier relying on this 
passive targeting has been clinically used and showed tumor accumulation, reduced 
clearance and reduced cardiotoxicity.28-29  
 
Figure 1.7 Cartoon representation of passive and active targeting mechanisms 
On the contrary of passive targeting, active targeting rely on the specific binding to the 
cancer cell surfaces. By incorporation of specific ligands to the nanocarriers that are 
complementary to receptors overexpressed on tumor cell surface, these nanocarriers 
promises to target cancer cells more effectively than EPR effect alone. Cellular targets 
usually used in the active targeting strategy involve the targeting of cancer cells and tumour 
endothelium receptors including transferrin, folate, epidermal growth factor receptor, 
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vascular endothelial growth factor, αvβ3 integrins and the Vascular Cell Adhesion 
Molecule-1 (VCAM-1) or matrix metalloproteinases (MMP's). 
The  amphiphiles formed nanoassemblies we have introduced hold great potential for 
targeting and drug delivery because their container properties. Drugs could be non-
covalently encapsulated by the nanoassembly and be protected from harsh environment. 
By installing stimuli-responsive functional groups, the drug molecules could be released 
in a controlled fashion. We have reported a nanogel system which contain a crosslinkable 
core and hydrophilic shell, which provide stable encapsulation of hydrophobic drug 
molecules.30-31 The disulfide crosslink could lock the drug molecules and then release them 
at intracellular GSH concentration. Post-modification through disulfide exchange enable 
ligands decoration so the nanogels could be armed with active targeting capabilities. 
 
Figure 1.8 Nanogel design and preparation for target delivery.30-31 
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1.5 Thesis overview 
 
This thesis will focus on design and synthesis of amphiphilic assemblies that hold great 
potential in areas such as sensing, cell targeting and drug delivery.  In Chapter 2, we 
outlined a simple and new strategy to design amphiphilic nanoassemblies that could 
respond to a combination of intrinsic trigger protein and extrinsic trigger light in an logic 
gated  (AND, OR, NOT) strategy, supramolecular disassembly and guest molecule release 
could then be achieved in a controlled fashion. 
Chapter 3, we have systematically studied the molecular weight effects and hydrophilic-
hydrophobic balance effects on enzyme induced supramolecular disassembly, which 
provide insights into the molecular design of enzyme-responsive systems. 
Chapter 4, we have designed a self-immolative nanogel platform for hydrophobic drugs 
delivery, with accessible functional group present on the surface, this nanogel can be easily 
functionalized with various receptors for targeted delivery.  
Chapter 5, we showed a novel approach for highly selective cell accumulation was 
designed by covalently masking and unmasking ligands on block copolymer based 
nanogels, such an ability will facilitate tumor imaging. 
Chapter 6, we designed a novel supramolecular approach that selectively transports water-
soluble globular proteins from an aqueous phase to the water-pool of a reverse micelle in 
an apolar organic phase. Proteins can maintain functions after crossing an incompatible 
solvent interface, which opens new possibilities for application of supramolecular 
assemblies in sensing, diagnostics and catalysis. 
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Chapter 6 showed the design of an enzyme nanoreactor for catalysis in apolar solvent and 
how to introduce crosslinks in the molecular assemblies, we will further try to control 
substrate permeability into the assembly to engineer unnatural selectivity in enzymes. 
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CHAPTER 2 
 PHOTOACTIVATION OF LIGANDS FOR EXTRINSICALLY AND 
INTRINSICALLY TRIGGERED DISASSEMBLY OF AMPHIPHILIC 
NANOASSEMBLIES  
Adapted with permission from Gao, J.; Liu, X.; Secinti, H.; Jiang, Z.; Munkhbat, O.; Xu, 
Y.; Guo, X.; Thayumanavan, S. Photoactivation of Ligands for Extrinsically and 
Intrinsically Triggered Disassembly of Amphiphilic Nanoassemblies. Chem. Eur. J. 2018, 
24, 1789-1794. © Copyright 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim 
 
2.1 Introduction 
  Supramolecular nanoassemblies that predictably respond to an environmental change 
have been of interest due to their implications in areas that range from material science to 
biomedicine 1-5. When designing molecular assemblies that have the potential to impact 
biomedicine, the input triggers can be classified into two main categories: extrinsic and 
intrinsic inputs.6-10 Extrinsic triggers have the advantage of offering external 
spatiotemporal control over the change in the properties of a molecular assembly, e.g. 
shining light at a specific location and time to disrupt a supramolecular assembly. 11-22 On 
the other hand, intrinsic triggers are directly correlated with an aberrant biological 
condition and therefore have the opportunity to be selective, e.g. lower pH at the 
extracellular space of disease tissues.23-27 Although both these systems present 
complementary advantages, the specificity offered by either of these systems by itself is 
insufficient. Therefore, a viable strategy would involve systems that would respond to a 
specific combination of extrinsic and intrinsic stimuli. We present a simple, new 
supramolecular approach that responds to a specific combination of extrinsic and intrinsic 
stimuli.  
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  We use proteins as the intrinsic trigger in our studies here, although the often-targeted 
intrinsic triggers are pH, reducing conditions, and reactive oxygen species.28-34 Proteins are 
challenging and interesting as inputs, because of their structural and functional fragility 
and because they are considered to be the primary cause of pathological imbalances in 
biology.35-39 We use light as the extrinsic trigger in these studies. In engineering the 
combinations of these two triggers, we were inspired by the molecular logic gates proposed 
and studied over past couple of decades.40-47 While there have been many reports on 
molecular logic gates involving small molecules,48-54 such gated strategies in nanoscale 
assemblies are relatively limited.55 We are particularly interested in developing systems 
that predictably respond to dual inputs, based on protein and light (Figure 2.1).  
 
Figure 2.1 Schematic representation of protein and light responsive nanoassembly. 
 
2.2 Results and discussion 
2.2.1 Proof of concept on small molecules 
  First, we targeted the design of a molecular assembly that would respond only in the 
presence of a specific protein and light, but not in the presence of either of these inputs by 
themselves or in their absence. Such a system is interesting, as they offer the best 
opportunity to be specific, because it requires the concurrent presence of two different 
stimuli. For the protein, we used bovine carbonic anhydrase (bCA). Primary aryl 
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sulfonamides are well established ligands for this protein, where the active site zinc is 
known to be engaged with the sulfornamide moiety.56-58 Examination of the structure of 
this binding interaction suggests that derivatizing the amino moiety of the sulfonamide 
group with an alkyl unit would cause this molecule to be not a good ligand for bCA.  If 
such a substituent were to be removed in the presence of light, then the ligand is rendered 
activatable by light.  Our design hypothesis is then that if such a functional group were to 
be then incorporated onto a protein-responsive assembly, then the assembly would respond 
only if there is both light and protein present, as shown in Figure 2.1. 
Scheme 2.1 Photo-induced cleavage of compound 1 to expose sulphonamide ligand 2 
 
Figure 2.2 1H NMR spectra of compound 1 in D-DMSO at various UV irradiation periods. 
The gradual decrease of peaks at 8.49 and 4.36 ppm, which is corresponding to imino and 
methylene group, indicated the photo-cleavage of o-nitrobenzyl group.  
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  To test this hypothesis, we first tested whether small molecule sulfonamide ligand can be 
protected by an o-nitrobenzyl moiety, which can then be released in the presence of light. 
Accordingly, we synthesized the molecule 1 and evaluated the possibility of deprotection 
of the nitrobenzyl moiety due to light irradiation at 365 nm (Figure 2.1).  Indeed, 1H NMR 
and LC-MS studies showed that the sulfonamide ligand was fully liberated to afford the 
sulfonamide ligand 2, in response to UV irradiation (Figure 2.2, 2.3). We also tested 
molecules 1 and 2 as the ligands for bCA using a 5-(Dimethylamino)-1-
naphthalenesulfonamide (DNSA) in a competitive displacement assay, the fluorescence 
emission at 460 nm formed by DNSA-bCA complex indicates whether DNSA is 
replaced.11 Our studies showed that when the ligand was masked in 1, it did not 
competitively remove DNSA, while the photo-cleaved product 2 was able to displace 
DNSA at a molar ratio of 1:1 for bCA and DNSA (Figure 2.4). 
 
Figure 2.3 LC-ESI-MS results of compound 1 upon UV irradiation. Green peak (m/z = 
335.0) is corresponding to compound 1. Pink peak (m/z = 200.0) is corresponding to 
compound 2: 4-carboxylbenzene-sulfonamide. This result indicated that sulfonamide is 
generated after UV irradiation. 
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Figure 2.4 Emission spectra of bCA, DNSA, bCA-DNSA complex, bCA-2 complex, CA-
1 complex irradiated by UV, competitive binding between 2 and DNSA. 
2.2.2 Protein AND light gated disassembly and guest release 
  To generate a nanoassembly that would predictably respond only to the concurrent 
presence of light irradiation and the protein, we took the structural components of molecule 
1 and install it into an amphiphilic dendrimer. The molecular structure that potentially 
serves this purpose is shown in Figure 2.5b as 3. The facially amphiphilic trimer contains 
an alkyl chain as the hydrophobic moiety and an oligoethylene glycol (OEG) chain as the 
hydrophilic moiety in each of the repeat units. The key functional group, N-(o-nitrobenzyl) 
benzene sulfonamide, is clicked on to the central unit on the hydrophilic face of the 
amphiphile using the Huisgen cycloaddition reaction. This amphiphile is known to 
aggregate to form nanoassemblies, which could then disassemble in response to a ligand-
protein binding because of the change in the hydrophilic-lipophilic balance (HLB) upon 
protein binding. We also hypothesized that this nanoassembly would disassemble only in 
response to both light and protein, but not to just one of these two inputs. When the 
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assembly is irradiated with light, the sulfonamide moiety would be liberated; this change 
however would not be sufficient to change the HLB of the assembly. Similarly, since the 
ligand moiety is masked, it would be unavailable for the binding-induced disassembly in 
response to the protein.  However, in the presence of both light and the protein, the 
nanoassembly should disassemble as the light would unmask the ligand, binding of which 
to the protein would cause a significant change in the HLB of the amphiphile. 
Figure 2.5. (a) Schematic representation of protein AND light gated disassembly and 
guest release, (b) Molecular structure of 3. 
 
Prior to testing this hypothesis, we characterized the nanoassembly, formed from molecule 
3. Synthetic details and the molecular characterization are shown in the SI. Since 3 contains, 
the nanoassembly formed would be an amphiphilic assembly, the critical aggregation 
concentration (CAC) can be estimated using the possibility of incorporating a hydrophobic 
molecule within the interiors of the assembly. The CAC for 3 was found to be ~36 μM. To 
assess the size of the nanoassembly formed, an aqueous solution of 3 was assessed using 
dynamic light scattering (DLS), at a concentration above its CAC (50 μM). The 
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amphiphilic nanoassembly was found to have an apprarent hydrodynamic diameter of >120 
nm (Figure 2.6a). The spherical morphology of the assembly was ascertained using 
transmission electron microscopy (TEM) (Figure 2.6c) and atomic force microscopy (AFM) 
(Figure 2.7). Size from TEM images showed that the observed aggregates are 
 
Figure 2.6 (a) Apparent hydrodynamic diameter(DH, app) of nanoassembly formed by 3 (50 
μM) determined by one-angle dynamic light scattering, and 3 in presence of bCA and UV 
after 48h, (b) DH, app of nanoassembly 3 in presence of UV, bCA, UV and BSA, TEM 
images of 3 (50 μM) in presense of (c) no inputs, (d) UV light, (e) bCA, (f) bCA and UV 
light, (g) DiI release from 50 μM 3 solution in response to UV and bCA, (h) Plot of % 
release of DiI. 
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slightly lower than those from DLS, this difference is likely due to the shrinkage of the 
particles in the dry state or due to overestimation of the size of the particles in DLS as it 
also includes hydration shells around the particles.  
  Next, to test our hypothesis that the nanoassembly from 3 would be sensitive to the 
concurrent presence of both light and proteins, we treated a 50 µM solution of 3 with 365 
nm light irradiation for 15 minutes and 60 µM bCA. We were gratified to find that the size 
of the assembly reduced from >120 nm to <10 nm (Figure 2.6a). To fully test whether this 
is indeed a response to the combination of these two inputs, effects of the light irradiation 
and the presence of bCA were tested independently. In both these cases, there was no 
discernible change in the size of the assembly, compared to the assembly of 3 itself (Figure 
2.6b). The size change in the presence of both stimuli, and lack thereof in the presence of 
either of these stimuli, were also confirmed by TEM (Figure 2.6c-f) and AFM (Figure 2.7). 
These results provided the first indicator that the system is only responsive to the presence 
of both stimuli. 
 
Figure 2.7 AFM images of 3 (50 μM) supramolecular micellar structures in aqueous 
solution in presence of (a) no inputs, (b) bCA, (c) UV light, (d) bCA and UV light. 
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  To test these findings further, we utilized the host-guest properties of the nanoassembly. 
Since 3 forms amphiphilic aggregates with a hydrophobic interior in the aqueous phase, it 
can function as a nanocontainer to host water-insoluble guest molecules. We envisaged 
that by taking advantage of this container-like feature and employing AND logic inputs to 
the nanoassemblies, we will be able to regulate the guest release profile. Here, we use 1,1'-
dioctadecyl-3,3,3'3'-tetramethyl-indocarbocyanine perchlorate (DiI), as the guest molecule 
to be entrapped inside the hydrophobic interior of 3. Encapsulation of DiI in this assembly 
was found to be quite stable with time, where there was a <10% change in the characteristic 
absorption of DiI over 48 hours (Figure 2.6h).  Similarly, when the 50 µM solution of 3 
was irradiated with light at 365 nm or when it was treated with 60 µM concentration of 
bCA,the change in absorption peak was small and indistinguishable from the assembly in 
the absence of any stimulus (Figure 2.6h). Interestingly however, a rather dramatic 
decrease in DiI absorption was observed in the presence of both light and bCA, where ~60% 
of the guest molecules were released from the assembly in ~6 hours and >80% of the 
molecules were released in 48 hours (Figure 2.6g, h). These data are all consistent with our 
hypothesis that our nanoassembly is programmed to respond only in the presence of both 
stimuli. However, it is important to show that the presumed disassembly and guest release 
is indeed due to specific protein-ligand binding. To test the specificity of the protein-ligand 
binding, we applied UV irradiation and bovine serum albumin (BSA), a protein that has no 
specific interaction with sulfonamide, as the simultaneous inputs to investigate the size 
transformation and guest release. Indeed, there was neither any change in the size of the 
nanoassembly nor was there any discernible guest release over 48 h. These results further 
validate that the assembly is specific in response to bCA. 
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Figure 2.8. (a) Molecular structure of 4, (b) DH, app of 4 nanoassembly (concentration of 4 
= 50 μM); (c) Plot of % release of DiI from 50 μM 4 solution. 
 
  Also, we were interested in another control experiment, where we utilize a structurally 
related amphiphile forms a similar nanoassembly, but lacks the features that respond to 
light or to the specific protein. In this case, we prepared the trimeric amphiphile, 4, in which 
every unit contains both hydrophobic alkyl chains and hydrophilic PEG moieties without 
any light sensitive moieties or protein-binding ligand functionalities. This molecule, too, 
forms a similarly sized nanoassembly in aqueous phase. Similar to the methods above, we 
studied the effects of individual and concurrent orthogonal inputs of UV light and bCA 
protein. No size transition or discernible guest release were observed, independent of 
whether a single input, no input, or both inputs were applied (Figure 2.8b and c). These 
results validate that the introduction of N-(o-nitrobenzyl) benzene sulfonamide ligand is 
critical for realizing the observed AND-gated disassembly and guest release.  
2.2.3 Protein OR light gated disassembly and guest release 
In dual responsive logic-gated systems, the next challenge in designing nanoscopic systems 
involves the OR gate, where a nanoassembly can respond to either of the inputs. To address 
this design challenge, we designed and synthesized the amphiphile 5, shown in Figure 2.9. 
This molecule contains a sulfonamide moiety in the middle repeat unit on the hydrophilic 
face of the amphiphile, similar to 3, but the bCA-ligand is present here in its unmasked 
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form. At the two terminal units, the hydrophobic decyl chain is linked to the trimeric 
scaffold using a photo-responsive o-nitrobenyzl ester linker. Synthetic details and are 
shown in the SI. We envisage here that when 5 is exposed to UV light, photo-induced 
cleavage of the nitrobenzyl ester will disconnect the long hydrophobic chain from the 
amphiphilic oligomer, while concurrently generating a carboxylic acid moiety. This 
transformation should render the entire oligomer much more hydrophilic, thus triggering 
disassembly. On the other hand, when treated with bCA, the already unmasked and 
available sulfonamide ligand should bind to the protein efficiently, causing a change in the 
HLB of the amphiphile to result in disassembly.  
 
Figure 2.9. (a) Schematic representation of OR logic gated disassembly and guest release, 
(b) Molecular structure of 5. 
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  To test these design hypotheses, the size transformation of a solution of 5 was evaluated 
using DLS. As shown in Figure 1.10e, either UV light or the bCA protein inputs induce a 
size change in the nanoassembly from ~150 nm to ~10 nm. TEM images of D2 before and 
after applying one or both inputs further confirm the disassembly event (Figure 2.10a-d). 
We also tested the host-guest properties of the assembly in the presence of these stimuli.  
Indeed, the DiI guest encapsulated in the D2 nanoassembly was released, when exposed to 
the bCA protein or the UV irradiation (Figure 2.10f). Note that the extent of molecular 
release with the protein binding is smaller than that of unmasked 3. This is expected, 
because the overall hydrophobicity of the interior of the assembly from 5 is significantly 
higher than that from 3, because of the introduction of additional aromatic   units in the two 
of the three hydrophobic units. In fact, aromatic-aromatic interactions have been shown to 
have a substantial effect on the stability of encapsulation of molecules in these 
nanoassemblies.12 Removal of these hydrophobic units, followed by treatment with the 
protein brings the guest release profile, comparable to that found with the unmasked 3. 
 
Figure 2.10. TEM images of 5 (50 μM) in presense of (a) no inputs, (b) UV light, (c) bCA, 
(d) bCA and UV light; (e) DH, app of 5 nanoassembly in response to UV and bCA, (f) Plot 
of % release of DiI. 
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2.3 Summary     
To summarize, we have demonstrated a set of amphiphilic supramolecular assemblies that 
can disassemble in the presence of an extrinsic physical stimulus (light) and an intrinsic 
biological stimulus (protein). Since these nanoassemblies are capable of sequestering 
hydrophobic guest molecules, the host-guest properties of the assemblies are also 
compromised in the presence of these inputs. We outline molecular designs that can 
respond to the presence of either one or both of these stimuli, as well as that would respond 
only to the concurrent presence of both stimuli. The latter system was developed by caging 
a protein-specific ligand with a photo-protecting group that masks the ligand from being 
available for protein binding and thus preventing binding-induced disassembly. Therefore, 
the nanoassembly requires the concurrent presence of both light and the specific protein 
for programmed disassembly. In the former scenario, where the nanoassembly responds to 
either of the inputs, the disassembly was achieved by strategically placing the light-
responsive moieties and the protein-responsive moiety in two different parts of the 
amphiphilic building block. As controlled responses to the concurrent presence of two 
different stimuli present the possibility of substantially increasing specificity in responses, 
the design insights provided here will find use in the design of novel protein-responsive 
drug delivery and controlled-release systems.  
2.4 Experimental procedures 
2.4.1 Materials and general methods 
  All the reagents were from commercial source and used as received. 1H NMR and 13C 
NMR spectra were recorded on a Bruker DPX-400 MHz NMR spectrometer using the 
residual proton resonance of the solvent as the internal standard. All molecules without 
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characterization data mentioned below were synthesized through well-established 
synthesis procedures previously reported by our group. [59-61] UV-vis absorption spectra 
were obtained by a Carry 100 Scan spectrometer. Fluorescence spectra were recorded on a 
PerkinElmer LS 55 spectrofluorimeter. Mass spectrometric data were collected by 
Capillary LC (Thermo Dionex Ultimate 3000)-ESI-MS (Bruker AmaZon quadrupole ion 
trap). 
Dynamic Light Scattering (DLS) Study: For the DLS measurements, 2 μmol of 3, 4 or 5 
was dissolved in 10 mL PBS buffer (pH 7.4, 10 mM) and stirred at 4 oC for overnight and 
then stored in room temperature as 200 μM stock solution. Then these oligomeric 
amphiphile solutions were diluted to 50 μM with PBS buffer and filtered using hydrophilic 
membrane (pore size 0.450 µm) before experiment was performed. The diluted samples 
were treated with UV irradiation (Black Ray UV lamp, 365 nm, 115 V ~ 60 Hz); bCA; UV 
irradiation followed the addition of bCA or UV irradiation followed the addition of BSA. 
The sizes of each solution were recorded overtime by a Malvern Nanozetasizer ZS90 with 
a 637-nm laser source with non-invasive backscattering technology detected at 173o using 
disposable sizing cuvette. Standard operating procedures (SOP) are set up including 
following parameters: the sample was equilibrated for 120 s at 25 oC before each 
measurement; the sizes were reported as the hydrodynamic diameter (DH) and each 
measurement average 16 runs were repeated three times; the data was automatically 
analyzed by the zetasizer software through Mie model which then give the view of count 
rate, correlation function, intensity particle size distribution (PSD), volume PSD and 
Number PSD after each measurement. 
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Transmission Electron Microscope (TEM) Study: The same sample for DLS measurement 
was dropped onto carbon-coated copper grid. The grid was dried by slow evaporation in 
air, and then dry separately in a vacuum overnight. Images were recorded on a JEOL-
2000FX electron microscopy operated at 200 kV and at a nominal magnification of 5000X. 
At least 10 locations on the TEM grid were examined. The assembly diameter was 
calculated using ImageJ software. 
Atomic force microscopy (AFM): AFM images were taken using a Brucker Dimensions 
3000 Scanning Probe Microscope under tapping mode. Silicon wafers [Cemat Silicon S.A., 
(111)-oriented] were pre-cleaned by sonication in ethanol and acetone for 20 min, 
respectively. Then the wafers were dried with Ar flow and treated with UV-O3 for 15 min. 
For AFM measurement, the oligomers at a concentration of 50 μM was drop-cast onto the 
corresponding substrate.  
DiI encapsulation: 50 μM oligomeric amphiphile solutions in PBS buffer were stirred at 
room temperature and DiI stock solution (1 mg/mL in acetone, 5 wt% to 3, 4 or 5) was 
added in each solution. The solutions were stirred for 8 h in room temperature, open to the 
atmosphere allowing the organic solvent to evaporate, and then filtered through hydrophilic 
membranes with pore size of 0.45 μm to remove unencapsulated DiI. 
Guest release study: DiI-encapsulated oligomeric amphiphile solutions (50 μM) were 
treated with 15 min UV irradiation; 60 μM bCA; 15 min UV irradiation followed the 
addition of 60 μM bCA or 15 min UV irradiation followed the addition of 60 μM BSA. 
The absorption spectra of DiI were recorded overtime. The % release of DiI was calculated 
by using the following equations: 
% Release of DiI = (It-I0)/It*100 
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I0 =the highest absorbance of DiI; It = the highest absorbance of DiI at each time point  
Calculation of critical aggregation concentration (CAC): A stock solution (1 mM) of 3/4/5 
micelle was prepared was diluted into various solutions of different concentrations. The 
concentration range of polymer was maintained from 0.1 mM to 0.001 mM. Nile Red was 
encapsulated to the micelle by adding 10 μL of Nile Red stock solution (20 μM in acetone). 
All the micelle solutions were kept uncapped overnight to evaporate the acetone. Then 
emission spectrum was recorded for each solution and emission maxima of each spectrum 
were plotted as a function of the concentration of 3/4/5. The inflection point of the plot was 
taken as CAC of polymer 3/4/5. 
2.4.2 Synthesis and characterization 
Scheme 2.2. Synthetic protocol of masked ligand 
 
Synthesis of compound 1: 4-(Chlorosulfonyl) benzoic acid (2.2 g, 10 mmol) was taken into 
a round bottomed flask along with 2-Nitrobenzylamine hydrochloride (1.89 g, 10 mmol) 
and dissolved in the co-solvent of acetone (100 mL) and H2O (25 mL). NaHCO3 (1.68 g, 
20 mmol) in H2O was then added to the reaction mixture. The solution was stirred for 
overnight, concentrated, followed with the addition of 100 mL H2O. The residue was 
extracted with 3×200 mL ethyl acetate, the organic phase was combined, concentrated and 
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purified by combiflash using DCM/methanol as eluant. The product was eluted at a polarity 
of 11% methanol in DCM and obtained as a light yellow solid. Yield: 27%. 1H NMR (400 
MHz, DMSO-d6, TMS): δ (ppm) = 8.49 (t, 1H), 8.08 (d, 2H), 7.97 (d, 1H), 7.69 (t, 1H), 
7.63 (d, 1H), 7.52 (t, 1H), 4.36 (d, 2H). 
Synthesis of compound 6: Compound 1 (268 mg, 0.8 mmol) and N-Hydroxysuccinimide 
(138 mg, 0.96 mmol) were dissolved in DMF (15 mL), followed with the addition of 
EDC·HCl (184 mg, 1.2 mmol). The solution was allowed to stir in room temperature for 
overnight. The reaction mixture was mixed with 50 mL DCM and washed with 3×30 mL 
H2O, 3×30 mL saturated NaHCO3 solution and 3×30 mL brine. The organic layer was 
collected and dried over anhydrous Na2SO4, concentrated and purified by combiflash using 
hexanes/ethyl acetate as eluant. The product was eluted at polarity of 50% ethyl acetate in 
hexanes and obtained as a light yellow solid. Yield: 88%. 1H NMR (400 MHz, CDCl3, 
TMS): δ (ppm) = 8.19 (d, 2H), 8.00 (d, 1H), 7.91 (d, 2H), 7.56 (m, 2H), 7.44 (t, 1H), 4.48 
(d, 2H), 2.93 (s, 4H). 
Synthesis of compound 7: Compound 2 (260 mg, 0.6 mmol) and triethylamine (112 
μL，0.8 mmol) were dissolved in 10 mL DCM and stirred. O-(2-Aminoethyl)-O’-(2-
azidoethyl) pentaethylene glycol (175 mg, 0.5 mmol) was dissolved in 5 mL DCM and 
added to the reaction mixture dropwise with the help of an addition funnel. The reaction 
was allowed to go on for overnight at room temperature, after which it was washed with 
2×10 mL H2O and 2×10 mL brine. The DCM layer was then dried over Na2SO4, 
concentrated and purified by combiflash using hexanes/ethyl acetate as eluant. The 
product was eluted at a polarity of 100% ethyl acetate and obtained as amber liquid. Yield: 
78%.1H NMR (400 MHz, CDCl3, TMS): δ (ppm) = 7.98 (d, 1H), 7.92 (d, 2H), 7.87 (d, 
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2H), 7.60 (d, 2H), 7.47 (m, 1H), 7.15 (s, 1H), 5.66 (t, 1H), 4.44 (d, 2H), 3.70-3.59 (m, 
26H), 3.36 (m, 2H). 
General procedure for click reaction： The mixture of dendritic acetylene compound (1.0 
eq), azide (2 eq for 1 acetylene group), CuSO4.5H2O (0.5 equiv.) and sodium ascorbate 
(0.5 eq.) in THF/H2O (1:1) solvent mixture was heated at 50 oC for 24 h. The reaction 
progress was monitored by TLC. After completion of the reaction, the reaction mixture 
was partitioned between ethyl acetate and saturated aqueous NH4Cl solution. The aqueous 
layer was extracted twice with ethyl acetate and the combined organic layer was dried over 
Na2SO4 and evaporated to dryness. The crude product was purified by silica gel column 
chromatography.  
Synthesis of 3: Synthetic protocol of 3 is outlined in scheme 2.3. 
Scheme 2.3. Synthetic protocol of targeted oligomer 3 
 
Synthesis of D1 (compound 5): Compound 8 was synthesized according to our previous 
report1. According to general procedure for click reaction, compound 8 (50 mg, 35 μmol) 
was treated with azide 7 (47 mg, 70 μmol) to give 52 mg of 3. Yield: 72%. NMR (400 
MHz, CDCl3) δ 7.96 (t, 3H), 7.82 (d, 2H), 7.71 (br, 1H), 7.59 (d, 2H), 7.54 (m, 1H), 7.40 
(t, 1H), 6.32 (s, 1H), 6.61 (m, 8H), 6.39 (t, 1H), 6.17 (t, 1H), 5.15 (s, 2H), 4.89 (s, 4H), 
4.66 (s, 2H), 4.41 (m, 4H), 4.09 (t, 4H), 3.90-3.36 (m, 68H), 3.36 (s, 6H), 1.76-1.18 (m, 
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48H), 0.95-0.80 (m, 9H); 13C NMR (400 MHz, CDCl3) δ 166.0, 160.4, 160.0, 159.0, 157.2, 
156.3, 147.9, 142.6, 142.4, 139.4, 138.4, 135.8, 134.0, 132.5, 131.6, 128.9, 128.2, 126.9, 
125.0, 119.3, 110.3, 106.2, 105.8, 104.8, 104.7, 100.9, 100.7, 71.9, 70.7, 70.6, 70.5, 70.5, 
70.4, 70.4, 70.3, 69.7, 67.9, 67.4, 65.0, 59.0, 53.4, 50.3, 44.8, 40.1, 31.9, 29.7, 29.6, 29.5, 
29.4, 29.3, 29.3, 29.3, 26.1, 26.0, 25.6, 22.7, 22.4, 14.1; ESI-TOF m/z 1067.4 [M+2Na]2+: 
Calculated: 1067.32, found: 1067.4 [M]++Na: Calculated: 2111.64, found: 2112.0. 
Synthesis of D2: Synthetic protocol of 5 is outlined in scheme 2.4: 
Scheme 2.4. Synthetic protocol of targeted dendrimer D2 
 
Synthesis of compound 11: EDC.HCl (328 mg, 1.68 mmol) and N, N- 
diisopropylethylamine (0.60 ml, 3.36 mmol) were added to a solution O-(2-Aminoethyl)-
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O’-(2-azidoethyl) pentaethylene glycol (500 mg, 1.4 mmol) and 4-
carboxybenzenesulfonamide (287 mg, 1.4 mmol) and HOBt (262 mg, 1.68 mmol) 
in dimethylformamide (5 ml) and stirred for 24 hours at room temperature under nitrogen. 
The solvent was removed in vacuo and the residue purified by column chromatography on 
silica gel eluting with dichloromethane:methanol (95:5) (by volume) to give compound 11 
as a colorless oil. Yield 87%. 1H NMR (CDCl3, 400 MHz) δ 7.77-7.84 (m, 4H), 7.56 (s, 
1H), 6.24 (s, 1H), 3.36-3.73 (m, 24H). ESI-MS m/z calcd for [M+Na]+: 556.21; found: 
556.3718. 
Synthesis of compound 13: Compound 12 was prepared following our previously reported 
procedure1. According to general procedure for click reaction, compound 12 (400 mg, 0.94 
mmol) was treated with azide 11 (600 mg, 1.18 mmol) to give 560 mg of 13. Yield: 63%. 
1H NMR (CDCl3, 400 MHz) δ 7.91 (br s, 1H), 7.77 (m, 4H), 7.56 (s, 1H), 6.7 (s, 1H), 6.58 
(s, 1H), 6.30 (m, 3H), 6.10 (br s, 1H), 4.64 (s, 2H), 4.53 (s, 2H), 4.46 (t, 2H), 4.21 (s, 4H), 
3.93 (m, 4H), 3.78-3.83 (m, 6H), 3.52-3.73 (m, 50H), 3.35 (s, 6H), 1.55 (m, 2H), 1.2-1.4 
(m, 14H), 0.88(m, 3H). ESI-MS m/z calcd for [M+Na]+: 959.45; found: 982.4715. 
Synthesis of compound 14: Compound 10 (280 mg, 0.29 mmol), K2CO3 (121 mg, 0.87 
mmol), 18-crown-6 (38 mg, 0.145 mmol) and compound 9 (305 mg, 0.638 mmol) were 
mixed together in anhydrous acetone (50 mL) and refluxed for 12 h under argon. After 
slowly cooling the reaction to room temperature and evaporating the solvent, the resultant 
mixture was dissolved in ethyl acetate and washed with water. The combined organic 
layers were dried over Na2SO4, concentrated under reduced pressure and the crude mixture 
was purified by silica gel chromatography with MeOH/ethyl acetate (6:94 v/v) to give 
compound 14 (135 mg, 27%). 1H NMR (CDCl3, 400 MHz) δ 7.94 (d, 2H), 7.79 (d, 2H), 
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7.56 (br s, 1H), 7.53 (s, 1H), 6.72 (s, 1H), 6.63 (s, 1H), 6.17~6.39 (m, 9H), 5.08 (s, 2H), 
4.64 (s, 2H), 4.53 (s, 2H), 4.46 (t, 2H), 4.21 (s, 4H), 3.93 (m, 4H), 3.78-3.83 (m, 6H), 3.52-
3.73 (m, 50H), 3.35 (s, 6H), 1.55 (m, 2H), 1.2-1.4 (m, 14H), 0.88(m, 3H). ESI-MS m/z 
calcd for C89H129N5O28SNa [M+Na]
 : 1770.85; found: 1771.5027, [M+2Na]2+ 896.7148. 
Synthesis of 5：According to general procedure for click reaction, compound 14 (100 mg, 
56 μmol) was treated with azide 10 (66 mg, 168 μmol) to give 66 mg of 5. Yield: 46%. 1H 
NMR (CDCl3, 400 MHz) δ 8.15 (d, 2H), 7.94 (d, 2H), 7.89 (s, 2H), 7.79 (d, 2H), 7.53 (s, 
1H), 7.48 (br s, 1H), 6.94 (m, 4H), 6.72 (s, 1H), 6.62 (s, 1H), 6.17~6.37 (m, 9H), 5.60 (s, 
4H), 5.48 (s, 4H), 5.02 (d, 6H), 4.63 (s, 2H), 4.4 (t, 2H), 4.15 (s, 4H), 4.02 (t, 6H), 3.91 (m, 
4H), 3.81 (m, 8H), 3.51-3.7 (m, 50H), 3.35 (s, 6H), 1.8 (m, 4H), 1.55 (m, 2H), 1.46 (m, 
4H), 1.2-1.5 (m, 38H), 0.88 (m, 9H); 13C NMR ( CDCl3, 100 MHz) δ 166.2, 165.95, 163.70, 
159.97, 159.15,157.16, 156.75, 156.35, 144.49, 144.10, 142.8, 139.82, 138.27, 137.91, 
136.06, 133.82, 128.37, 128.18, 127.08, 125.00, 124.05, 119.64, 114.67, 113.76, 110.49, 
107.54, 107.37, 104.95, 104.86, 101.77, 101.31, 71.89, 70.68, 70.54, 70.45, 70.38, 70.30, 
70.04, 69.79, 69.56, 69.30, 69.15, 68.79, 67.42, 65.06, 64.92, 63.57, 61.64, 58.99, 55.99, 
53.44, 51.25, 50.77, 50.18, 40.09, 31.89, 29.70, 29.59, 29.35, 29.31, 29.09, 28.98, 25.93, 
22.68, 14.13. ESI-MS m/z calcd for C127H185N13O38SNa [M+Na]+: 2555.26; found: 
2555.9831.  
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CHAPTER 3 
 TUNABLE ENZYME RESPONSES IN AMPHIPHILIC NANOASSEMBLIES 
THROUGH ALTERATIONS IN UNIMER-AGGREGATE EQUILIBRIUM  
 
Adapted with permission from Gao, J.; Wang, Hui.; Zhuang, J.; Thayumanavan, S. Tunable 
enzyme responses in amphiphilic nanoassemblies through alterations in unimer-aggregate 
equilibrium. Chem. Sci., 2019, 10, 3018-3024. © The Royal Society of Chemistry 2019. 
3.1 Introduction 
Enzymes, as one of the most essential macromolecules in living organisms, are known 
to catalyse more than 5000 biochemical reactions efficiently and serve a variety of 
functions in biological processes. [1] Therefore, dysregulation of enzymatic activities has 
been associated with many human pathologies. [2-4] In this context, introducing enzymes as 
stimuli to trigger specific responses in artificial supramolecular assemblies have been of 
interest, as these have potential in areas such as activity profile based biological imaging 
and drug delivery. [5-13] A promising design strategy that leads to such materials involves 
covalent incorporation of substrate functionalities in self-assembling molecules, such as 
amphiphilic macromolecules, where the specific catalytic actions of an enzyme covalently 
modify the substrate moiety. If it were to be designed such that the product of this 
enzymatic reaction exhibits distinctly different self-assembly features, compared to the 
substrate, then there exists a unique opportunity for programmable changes in the 
nanostructures and their host-guest properties.  
  Many supramolecular systems including polymeric nanoparticles, hydrogels, silica 
nanoparticles and gold nanoparticles have displayed adaptive behaviors toward enzymes. 
[14-23] Tunability in kinetics of the enzymatic response still remains a challenge, as it is 
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mainly influenced by two factors: accessibility of enzyme to substrate moiety and degree 
of difference in the host-guest properties between the reactant and product assemblies. In 
the case of amphiphilic assemblies, our group and others have shown that enzymatic 
activation usually occurs at unimeric state, where substrate is more accessible to enzyme  
 
Figure 3.1 Schematic representation of enzyme-induced disassembly and guest release 
from varied oligomeric assemblies. 
 
than their assembled micellar form.24,25 Following these findings, we have been interested 
in investigating how the reaction kinetics and the ensuing change in the host-guest 
characteristics would be affected by tuning unimer-aggregate equilibrium to alter the 
assemblies’ accessibility to the enzyme. Moreover, we were interested in identifying as to 
how structural changes in host assemblies, induced by an enzyme, would affect rate of 
disassembly and kinetics of guest molecule release. We envisaged that oligomeric 
amphiphiles would be an ideal choice to address this question, because: (i) these molecules 
have critical aggregation concentrations (CACs) that are quite low and compare very well 
with amphiphilic polymers; (ii) despite the fact that they do exhibit a low CAC, unlike 
polymers, these are amenable to a well-defined structure−property relationship study as the 
degree of oligomerization can be precise. Here we report a new modular design of 
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oligomeric amphiphiles with which a precise control over degree of polymerization (DP) 
and functional group placements in the scaffolds can be achieved (Figure 3.1). These 
oligomers are expected to self-assemble in aqueous phase and host hydrophobic guests at 
their interiors. By varying the DP and hydrophilic moieties of host molecules, we explore 
the molecular features that underlie the kinetics of enzymatic response in these 
supramolecular assemblies. 
3.2 Results and discussion 
3.2.1 Oligomer design and synthesis 
  Since enzymatic activation usually occurs at the unimeric state, where the substrate is 
more accessible to enzyme than their assembled micellar form, we envisaged that shifting 
the equilibrium between the unimer and the assembled state would provide an opportunity 
to alter the enzymatic reaction rate. Degree of polymerization is one of the key factors that 
can alter this equilibrium26-29 and thus change the accessibility of an enzyme to its substrate. 
To test this possibility, it is critical that all the designed amphiphiles possess the same 
hydrophilic-lipophilic balance (HLB). For this purpose, a series of oligomeric amphiphiles 
from dimer (2-EG5) to pentamer (5-EG5), have been synthesized (Scheme 3.1). To further 
evaluate the effects of DP on the enzymatic response, a polymer P-EG5 with ~14 repeating 
units was also synthesized. In these amphiphiles, penta-ethylene glycol (EG5) monomethyl 
ether moieties are installed as the hydrophilic functionality, while alkylated coumarin 
moieties are used as the hydrophobic units. Both these units are attached to the meta- 
positions of a benzoyl building block, which are then attached to well-defined oligoamines 
to generate amphiphiles with different degrees of oligomerization. In all these systems, the 
coumarin moiety is chosen as the covalently-appended model guest molecule. In order to 
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release this guest molecule in the presence of an enzyme, we use an acetal-ester linkage to 
connect the coumarin to the oligomer. The esterase-induced cleavage of the carboxylate 
moiety would create a hemi-acetal coumarin, which is hydrolytically unstable. This hemi-
acetal therefore rapidly hydrolyzes further to generate a highly fluorescent, 4-
methylumbelliferone. In addition to releasing this covalently attached molecule, this 
transformation also replaces an aryl moiety on the hydrophobic side 
of these amphiphiles with a carboxylic acid moiety. This change results in a significant  
Scheme 3.1. Molecular structures of oligomers: legends of each oligomer indicate 
increased degree of polymerization from 2-EG5 to P-EG5, EG5 indicates oligomers with 
five ethyleneglycol units, EG8 indicates oligomers with eight ethyleneglycol units as 
hydrophilic moiety.   
 
 
Scheme 3.2. Synthesis route of oligomers exemplified using 3-EG5  
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change in the HLB of the amphiphile. Note that this series of amphiphiles share all the 
common structural features including backbone, hydrophobic and hydrophilic 
functionalities; the only variation within this series of amphiphiles is DP. Therefore, this 
investigation allows us to inquire about the impact of this DP upon self-assembly and 
enzyme induced disassembly events.     
   In addition to DP, HLB of oligomers is another factor that impact the unimer-aggregate 
equilibrium. To test this possibility, with the same oligomer series above, we simply 
increased the length of the oligoethyleneglycol chain length from five to eight units. Thus, 
we synthesized four more oligomers 2-EG8, 3- EG8, 4- EG8, and 5- EG8 (Scheme 3.1). 
We hypothesized that the increase in hydrophilicity upon going from penta-ethylene glycol 
monomethyl ether (EG5) to octa-ethylene glycol (EG8) monomethyl ether would increase 
the dynamics of the unimer-aggregate equilibrium, which will then increase the availability 
of the substrate moiety for the enzymes.  In this study, we also test this hypothesis. 
   The amphiphilic oligomers were designed in such a way that they can be synthesized in 
a modular fashion, providing facile access to vary the number of repeating units and 
functional group placement. The synthetic routes for the target oligomers are exemplified 
by the synthesis of trimer 3-EG5 in Scheme 3.2. The 3,5-disubstituted-benzoyl chloride 
molecule 1a was reacted with N,N”-dimethyl  diethylenetriamine under basic conditions 
to generate the substituted oligoamine scaffold 1b. This molecule now contains the 
pentaethyleneglycol hydrophilic unit and the alkyne moiety to anchor the hydrophobic unit. 
The hydrophobic and fluorogenic enzyme substrate was then attached at all three repeat 
units of the oligomer using the Huisgen 1,3-dipolar cycloaddition reaction, the so-called 
“click” chemistry14, to yield the desired oligomer 3-EG5 (Scheme 3.2).  
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3.2.2 Nanoassembly preparation and characterization 
We first investigated whether these oligomeric amphiphiles would form aggregates in 
aqueous phase, since they contain both hydrophobic and hydrophilic moieties. If self-
assembly occurs, the interior of these assemblies would have the capability to non-
covalently encapsulate hydrophobic molecules.  To test this, the oligomers were directly 
dissolved in phosphate buffer and non-covalent incorporation of a solvatochromic dye, 
Nile Red, within these assemblies was attempted. We found that at lower concentrations 
of oligomers, the emission intensity of Nile Red was quite low. However, once the 
concentration of the oligomers reached a certain point, a rather sharp increase in emission 
intensity was observed. This onset point is taken to be the onset of hydrophobicity-driven 
aggregation, which is estimated to be the critical aggregation concentration (CAC) of these 
oligomers. As shown in Table 2.1, with DP increasing from 1 to 13, the CAC values of 
these oligomers vary from 75 μM to 0.58 μM (Figure 3.2). In general, oligomers with 
higher DP tend to aggregate at lower concentrations, despite the fact that the HLB of all 
Table 3.1. Summary of oligomer assembly characterizations including critical aggregation 
concentration and assembly size. 
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these oligomers are identical. At same DP, the systems with longer ethylene glycol chains 
as hydrophilic moiety exhibited higher CAC values. 
	
Figure 3.2 Critical aggregation concentration (CAC) of oligomeric assemblies. 
 
	
Figure 3.3 TEM images of oligomeric assemblies. 
  The solution phase sizes of these nanoassemblies were then measured by dynamic light 
scattering (DLS) at a concentration above their CACs. We observed an average 
hydrodynamic diameter ranging from ~100-300 nm for these assemblies (Table 3.1). The 
spherical morphology and size of these assemblies were further ascertained using 
transmission electron microscopy (TEM), as shown in Figure 3.3. 
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3.2.3 Covalently attached guest molecule release in presence of enzyme 
Note that we hypothesized that if the HLB of the oligomers were kept constant, then 
higher DP oligomeric amphiphiles would be hydrolyzed by enzyme at a slower rate than 
their lower DP counterparts. To test this, we first measured the enzymatic cleavage rates 
of all oligomers. Since the enzymatic reaction releases the fluorescent byproduct, 4-
methylumbelliferone, we were able to monitor the cleavage rates spectroscopically. For an 
accurate comparison, it is necessary that all these oligomer solutions are not only prepared 
at concentrations above their respective CACs, but also contain the same concentration of 
the substrate functionalities, regardless of their DP. To meet these two criteria, we prepared 
oligomer solutions that contain 200 μM enzyme substrates (based on coumarin), i.e. 100 
μM dimer, 66.7 μM trimer, 50 μM tetramer, and 40 μM pentamer, and then treated with 60 
nM esterase. As shown in Figure 3.4, a clear trend of the enzymatic reaction rate was 
observed for these oligomers with PEG as hydrophilic moieties, amphiphile 2-EG5 
exhibited the fastest enzymatic rate over 48 hours, systematically followed by 3-EG5, 4-
EG5 and 5- EG5. Moreover, when the same concentrations of enzyme and the substrate 
were used in the case of the 14-mer P-EG5, the molecular weight of which is comparable 
to polymers, little hydrolysis was observed from the emission spectra. These results are 
consistent with our hypothesis that the higher DP would result in slower enzymatic reaction 
rate, which in turn provides a convenient handle to tune reaction rates of enzymes and the 
resultant release of the covalently bound molecules.  
When same experiments were performed with the second series of oligomers (the EG8 
series) that contain longer ethylene glycol chains as the hydrophilic group, a similar trend 
was indeed observed, i.e. hydrolysis rate decreases for oligomers with higher DP. These 
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Figure 3.4. Enzymatic hydrolysis of oligomeric assemblies based on coumarin release a) 
oligomer assemblies with EG5 as hydrophilic moiety, b) oligomer assemblies with EG8 as 
hydrophilic moiety, enzymatic hydrolysis comparison between oligomer-EG5 and 
corresponding oligomer-EG8 c) - f). 
 
results again confirmed our hypothesis that amphiphiles with higher DP are less accessible 
to enzyme and thus more stable compared with oligomers with lower DP.  Meanwhile, 
comparison of the two series of oligomers also allows us to evaluate HLB effects on the 
enzymatic hydrolysis rates of these oligomers. Note that the basis for our hypothesis that 
the degree of oligomerization would causes slower reaction rate is that the dynamics of the 
unimer-aggregate equilibrium would be slower at higher DP. The results above support 
this hypothesis. If this were true, then it should also follow that if the hydrophilicity of 
these oligomers changes, the dynamics of the unimer-aggregate equilibrium would also be 
affected, which would in turn alter the sensitivity of these oligomers to enzyme. To test 
this idea, we compared the hydrolysis rates of EG5 oligomers and EG8 oligomers under 
the same experimental conditions. Interestingly, we observed that the cleavage rate of the 
covalently attached molecules from 2-EG5 and 2-EG8 were very similar (Figure 3.4c).  
  
 
50 
However, when the DP increases to trimeric or higher, n-EG8 oligomers with longer 
ethylene glycol chains indeed consistently exhibited faster cleavage, compared to their 
corresponding n-EG5 oligomers with shorter PEG chains (Figure 3.4d-f). These results 
suggest that lowering hydrophilicity of oligomers will make them more stable in presence 
of esterase. This is reasonably expected, because increase in hydrophilicity is expected to 
increase the dynamics in the unimer-aggregate equilibrium, which facilitates enzyme’s 
access to its substrate functionalities. We attribute the lack of significant difference 
between 2-EG5 and 2-EG8 assemblies to the fact that these low order oligomers are 
already sufficiently dynamic, such that there is no significant advantage to increasing the 
hydrophilicity of the oligomeric amphiphile from EG5 to EG8. 
3.2.4 Non-covalent guest molecule release in presence of enzyme  
Next, we were interested in evaluating the effect of the enzyme-induced change in the 
HLB of the amphiphiles upon their host characteristics for hydrohobic guest molecules. 
We were especially interested in identifying whether this anticipated molecular release 
event will follow a DP- and hydrophilicity- dependent trend observed in the covalent 
modification of the amphiphile. To test these, we encapsulated a hydrophobic fluorophore, 
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine (DiI), into these assemblies. The 
DiI-encapsulated oligomeric assemblies were treated with the esterase and the molecular 
release was assessed by fluorescence change. A change in fluorescence is anticipated in 
this case, because DiI molecule is insoluble in aqueous solutions and therefore precipitates 
out of solution, upon release from the hydrophobic pockets of these amphiphilic assemblies. 
As with the experiments above, the concentration of esterase and the substrate 
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functionalities in the oligomers were maintained for appropriate comparison of the relative 
rates of molecular release.  
Indeed, we found that the guest release depends on the DP of oligomers at constant HLB 
of the molecule, i.e. within the same oligomer series (EG5 or EG8 series). That is, 
assemblies from higher order oligomers exhibit the ability to more stably encapsulate the 
guest molecules and responds to the enzyme much more slowly, compared to the lower 
order oligomers (Figure 3.5). Also, assemblies with longer ethylene glycol chains can 
release guest molecules much faster at the same time range (Figure 3.5, 3.6). These results 
show that a precise control over the release kinetics of non-covalently encapsulated guest 
molecules can also be achieved by tuning the molecular structures.  
 
Figure 3.5. Non-covalent guest (DiI) release from nanoassemblies. 
 
  Comparison of data for the covalent molecular release based on the enzymatic cleavage 
of the substrate functionalities and the release of the non-covalently bound guest molecules 
revealed that the latter process lags behind the former process. The potential reason behind 
this difference is that the enzymatic cleavage of the covalently attached guest molecules 
happens first, which is followed by the loss in capability of the amphiphilic assemblies to 
hold the guest molecules to cause molecular release. In this scenario, the intermediate states 
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of the aggregated assemblies generated by the enzymatic reaction (e.g. only one of the 
coumarin moieties cleaved in a pentameric amphiphile) also can bind to guest molecules, 
but their relative ability to act as a host might be lower. This process in conjunction with 
the need for a critical concentration of DiI to cause its precipitation likely manifests itself 
as the lag in the non-covalent guest release, relative to the covalent modification of the 
oligomers by the enzyme. 
	
Figure 3.6. Comparison of non-covalent guest release kinetics between oligomer-PEG and 
oligomer-OEG. 
3.2.5 Assembly size transformation in response to enzyme 
 Since the enzymatic cleavage of hydrophobic groups seems to be the primary reason for 
assemblies to lose their stability and capability to hold guest molecules, it is likely that this 
enzyme reaction induces morphological changes of the aggregated assemblies. To test this  
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Figure 3.7. Size evolution of assemblies in presence of esterase in 48 hours. 
possibility, we monitored the temporal evolution of the size of these assemblies by DLS.   
We found that the size of assemblies change immediately after esterase was introduced to 
these systems. As shown in Figure 3.7, both 2-EG5 and 3-EG5 completely disassembled 
in presence of enzyme: the size of assembly 2-EG5 sharply decreased from ~240 nm to 
~20 nm, while assembly 3-EG5 formed a ~35 nm assembly from an initial size of ~220 
nm in 48 hours, this size change was also confirmed by TEM images which showed clear 
spherical structures initially but little visible aggregates after 48 hours of enzymatic 
reactions. However, the size of oligomers 4-EG5 and 5-EG5 remained relatively 
unchanged over the same timeframe. Furthermore, a similar trend of assembly size change 
was observed for n-EG8 oligomers with longer EG chains at same experimental conditions. 
While 4-EG8 and 5-EG8 were rather more stable in presence of enzyme, both 2-EG8 and 
3-EG8 completely disassembled in presence of enzyme at a faster rate compared with 
corresponding n-EG5 oligomers, respectively. These results suggested that enzymatic 
cleavage can induce the disassembly process. Also, both DP and HLB variations of 
oligomeric amphiphiles can alter the disassembly kinetics, which correlate well with the 
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guest release profiles of both covalently bound and non-covalently bound hydrophobic 
molecules. 
3.3 Summary 
  To summarize, two series of oligomeric amphiphiles were prepared to evaluate the 
possibility of tuning enzyme-induced changes in their self-assembly properties and host-
guest characteristics. We have shown that: (i) when the degree of oligomerization increases 
in the amphiphiles, the enzymatic reaction rate decreases. This offers a straightforward 
opportunity to tune the release kinetics of covalently-appended guest molecules. (ii) This 
reaction kinetics can also be tuned by varying the hydrophilic-lipophilic balance of the self-
assembling substrate molecule itself, where increase hydrophilicity accelerates the 
molecular release rates. (iii) In the assemblies where the enzyme-induced alteration in HLB 
occurs at a reasonable rate, i.e. in lower order oligomers, a significant change in size and 
morphology of the assemblies were also observed.  (iv) Non-covalently bound guest 
molecules can also be released from these amphiphilic assemblies in response to the 
enzyme-induced alteration in HLB, the trends of which closely follows those observed in 
the release of the covalently bound guest molecules. The trends in the enzymatic reaction 
rates and the change in the host-guest characteristics can be understood by correlating 
structural variations to change in the dynamics of unimer-aggregate equilibrium. Factors 
that lead to faster unimer-aggregate equilibrium dynamics lead to faster enzymatic 
response. Overall, this study provides two simple and straightforward approaches to 
altering enzyme-induced changes in amphiphilic assemblies, which in turn offer tunability 
in the release kinetics of covalently and non-covalently bound guest molecules from these 
assemblies. The findings presented here could provide a basis for designing enzyme 
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responsive materials with controlled release capabilities in materials and biomedical 
applications.   
3.4 Experimental procedures 
3.4.1 General Methods  
All the reagents were from commercial source and used as received. 1H NMR and 13C 
NMR spectra were recorded on a Bruker DPX-400 MHz NMR spectrometer using the 
residual proton resonance of the solvent as the internal standard. All molecules without 
characterization data mentioned below were synthesized through well-established 
synthesis procedures previously reported by our group.30-32 UV-vis absorption spectra were 
obtained by a Carry 100 Scan spectrometer. Fluorescence spectra were recorded on a 
PerkinElmer LS 55 spectrofluorimeter. Mass spectrometric data were collected by 
Capillary LC (Thermo Dionex Ultimate 3000)-ESI-MS (Bruker AmaZon quadrupole ion 
trap). 
For the DLS measurements, the sizes of each solution were recorded overtime by a Malvern 
Nanozetasizer ZS90 with a 637-nm laser source with non-invasive backscattering 
technology detected at 173o using disposable sizing cuvette.  
The same sample for DLS measurement was dropped onto carbon-coated copper grid. The 
grid was dried by slow evaporation in air, and then dry separately in a vacuum overnight. 
Images were recorded on a JEOL-2000FX electron microscopy operated at 200 kV and at 
a nominal magnification of 5000X. At least 10 locations on the TEM grid were examined.  
A stock solution (1 mM) of oligomer micelle was prepared was diluted into various 
solutions of different concentrations. The concentration range of polymer was maintained 
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from 0.2 mM to 0.001 mM. Nile Red was encapsulated to the micelle by adding 10 μL of 
Nile Red stock solution (20 μM in acetone). All the micelle solutions were kept uncapped 
overnight to evaporate the acetone. Then emission spectrum was recorded for each solution 
and emission maxima of each spectrum were plotted as a function of the concentration of 
each oligomer. The inflection point of the plot was taken as CAC of each oligomer. 
For DiI encapsulation, oligomeric amphiphile solutions in phosphate buffer were stirred at 
room temperature and DiI stock solution (1 mg/mL in acetone, 5 wt% to oligomers) was 
added in each solution. The solutions were stirred for 8 h in room temperature, open to the 
atmosphere allowing the organic solvent to evaporate, and then filtered through hydrophilic 
membranes with pore size of 0.45 μm to remove unencapsulated DiI. 
For guest release study, DiI-encapsulated oligomeric amphiphile solutions (50 μM) were 
treated with esterase. The absorption spectra of DiI were recorded overtime. 
The % release of DiI was calculated by using the following equations: 
% Release of DiI = (It-I0)/It*100 
Where I0 =the highest absorbance of DiI 
      It = the highest absorbance of DiI at each time point  
3.4.2. Synthetic procedures  
General procedures for synthesis of molecule b: Oligoamine (1 eq.) was dissolved in dry 
tetrahydrofuran (THF), trienthylamine (2 eq. for 1 amine group) was added to the solution 
and stirred for 15 minutes at 0oC. A solution of benzoyl chloride molecule 1a (1.2eq for 
one amine group) in THF was added to the mixture dropwise and then stirred at room 
temperature overnight. Solvent was evaporated and then redissolved in dichloromethane, 
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then washed with water for three times. The organic layer was dried over Na2SO4 and 
evaporated to dryness. The crude product was purified by silica gel column 
chromatography.  
General procedures for synthesis oligomers: The mixture of oligomeric acetylene 
compound b (1.0 eq.), azide 1c (2 eq. for 1 acetylene group), CuSO4.5H2O (0.5 eq.) and 
sodium ascorbate (0.5 eq.) in THF/H2O (1:1) solvent mixture was heated at 50 oC for 24 h. 
The reaction progress was monitored by TLC. After completion of the reaction, the reaction 
mixture was partitioned between ethyl acetate and saturated aqueous NH4Cl solution. The 
aqueous layer was extracted twice with ethyl acetate and the combined organic layer was 
dried over Na2SO4 and evaporated to dryness. The crude product was purified by silica gel 
column chromatography.  
3.4.3 Characterizations for oligomers  
2-EG5: Yield: 94%. 1H NMR (400 MHz, CDCl3, TMS): δ (ppm) 7.63 (s, 2H), 7.55 (d, J = 
8.8 Hz, 2H), 6.99-6.94 (m, 4H), 6.59-6.55 (m, 6H), 6.17 (s, 2H), 5.80 (s, 4H), 5.15 (s, 2H), 
5.01 (s, 2H), 4.27 (t, J = 5 Hz, 4H),  4.01-3.54 (m, 40H), 3.36 (s, 6H), 3.05 (s, 4H), 2.41-
2.35 (m,10H), 1.89 (m, 4H), 1.63 (m,8H), 1.33 (m, 4H). 13C NMR (100 MHz, CDCl3) δ 
(ppm) 171.98, 171.36, 160.92, 159.43, 154.89, 152.37, 138.18, 125.92, 115.18, 113.18, 
112.95, 105.89, 105.53, 103.38, 84.70, 71.91, 70.73, 70.56, 70.54, 70.48, 69.52, 67.63, 
61.82, 59.01, 44.51, 37.92, 33.68, 29.79, 25.86, 23.90, 18.70. MALDI-ToF m/z 1618.593 
(C80H106N8O26+Na+ requires 1617.738). 
3-EG5: Yield: 90%. 1H NMR (400 MHz, CDCl3, TMS): δ (ppm) 7.69-7.64 (m, 3H), 7.55 
(d, J = 8.8 Hz, 3H), 6.98-6.94 (m, 6H), 6.56-6.52 (m, 9H), 6.17 (s, 3H), 5.80 (s, 6H), 5.18-
4.92 (m, 6H), 4.31-4.27 (m, 6H), 4.12-3.52 (m, 62H), 3.36 (s, 9H), 3.05-2.99 (d, J = 13.6 
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Hz, 3H), 2.65 (s, 3H), 2.40-2.38 (m, 15H), 1.89 (m, 6H), 1.63 (m, 12H), 1.33 (m, 6H). 13C 
NMR (100 MHz, CDCl3) δ (ppm) 171.97, 160.90, 160.03, 159.87, 159.40, 159.23, 154.84, 
152.42, 137.67, 125.93, 115.15, 113.16, 112.88, 105.51, 103.34, 84.67, 71.86, 70.68, 70.50, 
70.43, 69.47, 67.71, 61.91, 58.97, 50.33, 33.65, 29.74, 25.84, 23.87, 18.68. MALDI-ToF 
m/z 2414.982 (C120H158N12O39+Na+ requires 2414.107). 
4-EG5: Yield: 76%. 1H NMR (400 MHz, CDCl3, TMS): δ (ppm) 7.72 (m, 4H), 7.55 (d, J 
= 4.4 Hz, 4H), 7.01-6.94 (m, 8H), 6.59-6.53 (m, 12H), 6.19 (s, 4H), 5.80 (s, 8H), 5.31-5.02 
(m, 8H), 4.32 (m, 8H),  4.13-3.54 (m, 80H), 3.37 (s, 12H), 3.05 (m, 4H), 2.64 (m, 3H)2.42-
2.39 (m,20H), 1.89 (m, 8H), 1.71 (m, 16H), 1.33 (m, 8H). 13C NMR (100 MHz, CDCl3) δ 
(ppm) 171.99, 160.91, 159.86, 154.86, 152.41, 125.93, 115.16, 113.16, 112.90, 103.36, 
103.17, 84.68, 71.88, 70.68, 70.59, 69.48, 67.59, 58.99, 50.07, 33.87, 29.80, 25.83, 23.89, 
18.69. MALDI-ToF m/z 3211.185 (C160H210N16O52+Na+ requires 3210.476). 
5-EG5: Yield: 78%. 1H NMR (400 MHz, CDCl3, TMS): δ (ppm) 7.73 (m, 5H), 7.53 (d, J 
= 4.2 Hz, 5H), 6.97-6.94 (m, 10H), 6.52 (m, 15H), 6.16 (s, 5H), 5.80 (s, 10H), 5.29-4.95 
(m, 10H), 4.29 (m, 10H),  4.13-3.54 (m, 128H), 3.37 (s, 15H), 2.96(m, 4H), 2.61 (m, 4H), 
2.39-2.36 (m,25H), 1.89 (m, 10H), 1.68 (m, 20H), 1.34 (m, 10H). 13C NMR (100 MHz, 
CDCl3) δ (ppm) 171.99, 160.90, 160.05, 159.42, 154.85, 152.42, 137.73, 125.96, 115.15, 
113.16, 112.89, 105.85, 103.37, 84.75, 71.88, 70.50, 69.50, 67.72, 58.99, 33.68, 29.67, 
25.99, 23.89, 18.71. MALDI-ToF m/z 4007.328 (C200H262N20O65+Na+ requires 4006.845). 
P-EG5: Yield: 80%. 1H NMR (400 MHz, CDCl3, TMS): δ (ppm) 7.71, 7.53, 6.94, 6.45, 
6.13, 5.78, 5.07, 4.91, 4.25, 3.60-3.33, 2.38, 1.83, 1.62, 1.31. 13C NMR (100 MHz, CDCl3) 
δ (ppm) 172.02, 160.87, 159.98, 159.44, 154.83, 152.50, 137.69, 126.04, 115.12, 113.10, 
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112.83, 105.15, 103.38, 84.71, 71.87, 70.46, 70.45, 62.32, 67.57, 58.97, 49.92, 33.66, 29.82, 
25.83, 23.89, 18.69. THF GPC: Mw 12 kDa, PDI 1.08.  
2-EG8: Yield: 92%. 1H NMR (400 MHz, CDCl3, TMS): δ (ppm) 7.63 (s, 2H), 7.54 (d, J = 
4.4 Hz, 2H), 6.95 (m, 4H), 6.59-6.52 (m, 6H), 6.17 (s, 2H), 5.80 (s, 4H), 5.15 (s, 2H), 5.01 
(s, 2H), 4.28 (t, J = 3.6 Hz, 4H),  4.11-3.53 (m, 60H), 3.36 (s, 6H), 3.05 (s, 3H), 2.71(s, 
2H), 2.41-2.37 (m,10H), 1.89 (m, 4H), 1.69 (m, 8H), 1.33 (m, 4H).  13C NMR (100 MHz, 
CDCl3) δ (ppm) 171.98, 160.92, 159.91, 159.42, 154.87, 152.39, 138.16, 125.92, 123.11, 
115.17, 113.17, 112.92, 105.86, 105.51, 103.36, 103.21, 84.67, 71.90, 70.70, 70.52, 70.46, 
69. 50, 67.60, 61.96, 59.01, 49.99, 33.67, 29.84, 29.68, 25.80, 23.89, 18.69. MALDI-ToF 
m/z 1882. 356 (C92H130N8O32+Na+ requires 1881.879). 
3-EG8: Yield:69%. 1H NMR (400 MHz, CDCl3, TMS):δ (ppm) 7.69-7.67 (m, 3H), 7.55 
(d, J = 4.4 Hz, 3H), 6.98-6.95 (m, 6H), 6.56-6.51 (m, 9H), 6.17 (s, 3H), 5.80 (s, 6H), 5.18-
4.92 (m, 6H), 4.29 (m, 6H), 4.12-3.52 (m, 98H), 3.36 (s, 9H), 3.05-2.99 (d, J = 13.2 Hz, 
3H), 2.65 (s, 3H), 2.40-2.35 (m, 15H), 1.89 (m, 6H), 1.63 (m, 12H), 1.34 (m, 6H).13C NMR 
(100 MHz, CDCl3) δ (ppm) 171.96, 160.90, 160.04, 159.40, 154.84, 152.41, 137.91, 
125.93, 115.15, 113.16, 112.88, 105.86, 103.34, 84.67, 71.87, 70.68, 70.49, 69.48, 67.69, 
61.86, 58.98, 50.23, 33.65, 29.76, 25.82, 23.87, 18.68. MALDI-ToF m/z 2810.593 
(C138H194N12O48+Na+ requires 2810.342). 
4-EG8: Yield: 77%. 1H NMR (400 MHz, CDCl3, TMS): δ (ppm) 7.69 (m, 4H), 7.53-7.51 
(d, J = 4.2 Hz, 4H), 6.96-6.93 (m, 8H), 6.53-6.50 (m, 12H), 6.15 (s, 4H), 5.79 (s, 8H), 5.01-
4.95 (m, 8H), 4.27 (m, 8H), 4.13-3.54 (m, 120H), 3.36 (s, 12H), 2.97 (s, 3H), 2.71-2.58 (m, 
3H), 2.39-2.34 (m, 20H), 1.89 (m, 8H), 1.65 (m, 16H), 1.33 (m, 8H). 13C NMR (100 MHz, 
CDCl3) δ (ppm) 172.07, 160.86, 160.05, 159.86, 154.85, 152.40, 137.67, 125.95, 115.14, 
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113.14, 112.88, 105.48, 103.35, 84.69, 71.88, 70.68, 70.50, 69.50, 67.71, 59.00, 53.51, 
46.06, 33.91, 29.66, 26.06, 25.88, 18.69. MALDI-ToF m/z 3738.234 (C184H258N16O64+Na+ 
requires 3738.788). 
5-EG8: Yield: 82%. 1H NMR (400 MHz, CDCl3, TMS): δ (ppm) 7.73 (m, 5H), 7.55-7.53 
(d, J = 4.2 Hz, 5H), 7.00-6.95 (m, 10H), 6.51 (m, 15H), 6.16 (s, 5H), 5.80 (s, 10H), 5.19-
4.96 (m, 10H), 4.29 (m, 10H),  4.08-3.51 (m, 166H), 3.36 (s, 15H), 2.96(m, 3H), 2.61 (m, 
3H), 2.40 (m,25H), 1.88 (m, 10H), 1.65 (m, 20H), 1.31 (m, 10H).  13C NMR (100 MHz, 
CDCl3) δ (ppm) 172.01, 160.92, 160.07, 159.44, 154.87, 152.43, 125.97, 115.17, 113.18, 
112.91, 106.20, 103.39, 84.75, 71.90, 70.52, 69.52, 67.61, 59.02, 33.70, 29.69, 25.95, 23.91, 
18.73. MALDI-ToF m/z 4667.821. (C230H322N20O80+Na+ requires 4667.235).   
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CHAPTER 4 
 PERIPHERY FUNCTIONALIZABLE SELF-IMMOLATIVE NANOGEL FOR 
TARGET DELIVERY INTO CYTOSOL AND SUBCELLULAR ORGANELLES  
 
4.1 Introduction 
  Nanoparticles as drug delivery vehicles have displayed huge potential to combat the 
implications that are always associated with traditional drug administration methods1-2, 
such as fast clearance, poor solubility and off target effects. By delivering the exact dose 
of therapeutic drugs to a specific disease site, nanoparticles could level up the therapeutic 
efficiency and safety.3-6 To date, various materials include dendrimers, polymers, gold 
nanoparticle, silica nanoparticle and liposome have been exploited towards either 
improving cargo loading efficiency, targeting capability or controlling the drug release.7-14 
Current challenges in this emerging field involve the design of nanoparticles displaying 
multiple features, and in particular, converging all these merits into one simple platform  
without compromising synthetic ease and attractive features. Self-immolative polymers 
provided an opportunity for programmed fragmentation and triggered release from 
peripheral functional groups, which could promote advanced drug delivery but require 
extensive synthesis.15-20 Previously our group have introduced an emulsion-free method to 
prepare crosslinked nanogels which can sequester hydrophobic guest molecules in aqueous 
media and release them in response to a biologically relevant stimulus.21-23 However, the 
post-functionalization through disulfide-exchange offers limited efficiency and could 
induce loss of encapsulation stability due to the cleavage of hydrophobic functional groups. 
  We envisaged that a periphery functionalizable self-immolative nanogel platform would 
be an ideal system for targeted drug delivery into cytosol or subcellular organelles (Figure 
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4.1). The primary requirements for this platform to meet are: 1) ease of synthesis, 2) high 
drug loading capacity, 3) fast triggerable release, 4) facile post-functionalization, 5) 
targeting capability. We hypothesized that incorporation of cross-linkable hydrophobic 
units in an amphiphilic polymer, with triggerable self-immolative feature, would generate 
nanoassemblies with capabilities to hold guest molecules and release them in response to 
an environmental stimulus. Meanwhile, introducing a reactive handle on the surface of 
nanogels would provide easy access to install various ligands for targeted delivery.  
 
Figure 4.1. Illustration of functionalized nanogel for targeted delivery into cytosol and 
subcellular organelles.  
 
4.2 Results and discussion 
4.2.1 Molecular design and synthesis 
  To this end, an amphiphilic block copolymer P1 that satisfies all the above requirements 
is synthesized through RAFT polymerization, which contains amine terminated 
polyethyleneglycol (PEG5000) as the hydrophilic moiety and carbonate bridged pyridyl 
disulfide (PDS) as the hydrophobic moiety (Scheme 4.1). Polymers with varied repeating 
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units of PDS were synthesized for optimizaiton of drug loading (table 4.1). The key 
premise of this molecular design here is that once this polymer self-assembles, it will 
generate nanoparticles with a functionalizable surface with amine as the reactive handle, 
and a hydrophobic core that is crosslinkable and responsive to highly reductive intracellular 
environment. The cleavage of disulfide will further cleave the carbonate to make the 
polymer completely hydrophilic, which will benefit the payload release. 
Scheme 4.1 Functional nanogel preparation illustration (a) and reaction scheme for 
polymer synthesis (b) and mechanism for redox triggered decrosslinking and self-
immolation.  
 
Table 4.1 Characterization data of polymers synthesized 
 
PEG:PDS Ratio
Mn
(kDa)
Mw
(kDa)
Ð
1:10 11.1 12.7 1.15
1:20 13.6 13.9 1.02
1:30 13.1 15 1.14
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4.2.2 Nanogel preparation and characterization 
  To test our design, polymer P1 was distributed in phosphate buffer (10 mM, pH 7.4), 
nanoassemblies with a size ~105 nm was observed from dynamic light scattering (DLS) 
shown in Figure 4.2a. Following this step, addition of dithiothreitol (DTT) would induce 
the crosslinking of the nanoparticle core through cleavage of PDS groups and results in the 
formation of nanogels, the crosslinking density can be quantitatively determined by the 
pyridothione released. Size of the crosslinked nanogels is similar to the initial 
nanoaggregates (Figure 4.2a), the spherical morphology was also confirmed by 
transmission electron microscopy (TEM) as shown in Figure 4.2c. It is noteworthy that free 
thiol generated after PDS cleavage could potentially trigger the polymer self-immolation, 
which competes with the crosslinking reaction. After monitoring the crosslinking reaction 
with varied amount of DTT using NMR, we figured out that self-immolation of the polymer 
proceeded only when excess DTT (higher than 0.5 equivalence of PDS group) is present  
 
Figure 4.2. a) DLS profile of micelles before and after crosslinking by DTT, b) DLS profile 
of micelles treated with varied amount of DTT, TEM images of nanogels treated with 
varied amount of DTT c) 0.25 eq, d) 0.5 eq, e) 1eq, scale bar 100nm. 
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(Figure 4.3). This is further confirmed by monitoring the size of these assemblies with 
different concentration of DTT, as shown in figure 4.2b-e, deficient amount of DTT (less 
than 0.5 eq. of PDS group) resulted in a crosslinked nanogel that is similar in size to the 
micelles, while excess DTT would degrade the assemblies. The findings here equipped the 
nanogel with interesting features such as proper size, crosslinkable core and triggerable 
degradation. 
 
Figure 4.3. NMR of micelle solution in presence of different amount of DTT, peak a and b 
indicates the self-immolated polymer, which was only observed when excess amount of 
DTT (more than 0.5 eq.)was added. 
 
  We anticipated the amine functional group located at the terminus of hydrophilic PEG 
chain would present at the surface of the nanogel, which could provide free access to for 
independent post functionalization. This possibility was tested by adding fluoresceinamine, 
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an amine reactive fluorescent molecule, to the nanogel solution. Since fluoresceinamine 
itself is non-fluorescent in buffer, the strong emission peak generated from the nanogel 
solution suggested the successful covalent labeling reaction (Figure 4.4a). Surface zeta 
potential change from positive to negative also confirmed this post-modification event 
(Figure 4.4b). 
 
Figure 4.4 a) Emission spectrum of nanogel treated with fluoresceinamine, b) Zeta 
potential of nanogel before and after reaction with fluoresceinamine, c) Absorption of 
encapsulated DiI in nanogel for 1 day and 14 days, d) DiI release from the nanogel in 
presence of 10 mM/10 uM GSH. 
 
  The capability of encapsulating guest molecules was firstly evaluated with 1,1'-
dioctadecyl-3,3,3'3'-tetramethyl-indocarbocyanine perchlorate (DiI). Encapsulation of DiI 
achieved over 96% loading efficiency and was found to be extremely stable in the 
crosslinked nanogel within two weeks, indicated by the characteristic absorption of DiI 
(Figure 4.4c). We are then interested to see whether the trapped guest molecules can be 
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released efficiently in response to a biologically relevant stimulus. We expected that 
glutathione (GSH), with millimolar concentration level in cytosol, would cleave the 
disulfide crosslinking and induce the release guest molecules. High concentration of GSH 
will also facilitate the self-immolation of the carbonate bond and result in huge decrease of 
the hydrophobicity of the nanogel, which could further promote the guest release. To test 
this, we treated the dye-loaded nanogel solutions with different concentrations of GSH (10 
μM and10 mM, correspond to extra- and intra-cellular level GSH concentrations) and 
investigated their release profiles by tracing the decrease of the hydrophobic dye’s 
absorption caused by its insolubility in aqueous media. The nanogel was able to hold most 
of the guest molecules at low GSH concentration, but at high GSH concentration, 83% of 
loaded cargo was released in 72 hours, which is much more efficient compare with previous 
reported system (Figure 4.4d).21,24 Followed by these observations, two different 
chemotherapy drugs, paclitaxel (PTX) and doxorubicin (DOX), were encapsulated in the 
nanogel. By modifying the drug feeding ratio from 10 wt% to 30 wt%, crosslinking density 
from 10% to 30% and hydrophobic repeating units of polymer from 10 to 20, 24.3 wt % 
and 6.5 wt % loading capacity were achieved for PTX and DOX using polymer P1 with 
20% crosslinking, respectively (Table 4.2). 
Table 4.2. Optimization of drug loading capacity.  
 
Variations Result: loading capacity
Trial # a. X-linking
10% 20% 30%
b. Drug feeding
10% 20% 30%
c. PEG:PDS ratio
110 120
Doxorubicin Paclitaxel
1 a1 b1 c1 2.90.13% 6.30.1%
2 a1 b2 c1 4.80.08% 10.20.21%
3 a1 b3 c1 5.50.12% 22.30.13%
4 a1 b1 c2 3.10.05% 6.20.08%
5 a1 b2 c2 4.40.11% 13.70.13%
6 a1 b3 c2 4.90.09% 23.70.12%
7 a2 b3 c1 6.50.07% 24.30.15%
8 a3 b3 c1 5.10.14% 21.10.22%
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4.2.3 Cytosolic drug delivery 
These nanogels themselves are nontoxic to cells such as 293T and MDA-MB-231 cells 
even at high concentrations, which provides the opportunity to act as drug delivery system 
(Figure 4.5). With these exciting features of this nanogel system, we are interested to 
explore the capability of this nanogel to deliver chemotherapeutic drugs into cytosol or 
even subcellular organelles in cancer cell lines. Folate receptors have been known to be 
overexpressed in malignant tumors25-27, which hold potential for folate-based tumor 
imaging and drug delivery.25,28 We envisaged that decoration the nanogel with folic acid 
could enhance the nanogel uptake in folate positive cells (Figure 4.6a). To test this, folic 
acid decorated nanogel (FA-Nanogel) was labeled with Cy3 dye to monitor cellular uptake 
in folate positive breast cancer cell MDA-MB-231 and folate negative cell HepG2. After 3 
hours incubation, significant red fluorescence was observed in MDA-MB-231 cells using 
confocal laser scanning microscopy (CLSM), but limited fluorescence signal was found in 
HepG 2 cells, indicating folic acid could enhance the uptake towards FR positive cells 
(Figure 4.6b,c). Next, we evaluated cell viabilities of MDA-MB-231 cells with nanogels 
using MTT assay. Empty nanogels were barely toxic even at high concentrations, but the 
PTX loaded nanogel lower cell viabilities by 40% and FA-nanogel was found to be more 
efficient to induce cell death, suggesting PTX has been delivered into the cells efficiently. 
 
Figure 4.5. Cell viability of control nanogels at varied concentrations. 
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Notably, increasing the folic acid content on nanogel from 25% to 100% (molar ratio to 
PEG chain) also resulted in a decrease in cell viability (Figure 4.6d).  
 
Figure 4.6. Efficient cytosolic delivery into MDA-MB-231 cells using folic acid 
functionalized nanogel. a) Functionalization of nanogel with Cy3 and folic acid, b) cellular 
uptake of control nanogel (b) and folic acid functionalized nanogel (c) after 3 h incubation 
(red, cy3-nanogel; blue, heochst). c) Cell viability of empty nanogel and PTX loaded 
nanogel with varied folic acid content from 0 to 100% (eq. per PEG chain). 
 
4.2.4 Targeted drug delivery into mitochondria 
  To test the versatility of our system, we were interested in the potential of this strategy for 
subcellular organelle targeting. Mitochondria, as key regulators of cell apoptosis, necrosis 
and autophagy, has been an attractive drug target.29-31 PTX has been shown to act on 
mitochondria triggering apoptosis but normally only a fraction of drug molecules is 
available to mitochondria due to multiple interactions with other cell compartments,32,33 
the drug efficiency would be significantly improved if it can be specifically delivered into 
the mitochondria. To this end, triphenyl phosphinium (TPP)31,34, a molecular motif 
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targeting mitochondria, was decorated on the surface of nanogels (Figure 4.7a). 
Mitochondria localization of TPP-nanogel was then assessed in MDA-MB-231 cells using 
CLSM. Colocalization of the red dots (from the Cy3-TPP-nanogel) and green dots (from 
mitotracker green) as shown in figure 4.7c suggested the nanogels accumulated in the 
mitochondria. In vitro cytotoxicity of PTX loaded TPP nanogel was then evaluated in 
MDA-MB-231 cells. Control nanogels was indeed nontoxic, but when treated the cells with 
PTX loaded nanogel, the cell viability decreased to 66%. Additionally, with TPP decoration 
from 25% to 100% (molar ratio to PEG chain), the therapeutic effect of PTX could be 
significantly enhanced, as suggested by the cell viability decrease from 57% to 31% 
(Figure 4.7d).  
 
Figure 4.7. Targeted delivery into mitochondria in MDA-MB-231 cells using triphenyl 
phosphinium functionalized nanogel. a) Functionalization of nanogel with Cy3 and TPP, 
b) cellular uptake of control nanogel (b) and folic acid functionalized nanogel (c) after 3 h 
incubation (red, cy3-nanogel; green, mitotracker; orange, merged two channels). c) Cell 
viability of empty nanogel and PTX loaded nanogel with varied TPP content from 0 to 100% 
(eq. per PEG chain). 
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4.2.5 Targeted drug delivery into nucleus 
  To further validate the applicability, we loaded our nanogel with another chemotherapy 
drug DOX and then functionalized the nanogel with benzene boronic acid (BB) (Figure 
4.8.a), aiming to target cell nucleus, where the drug could maximize its efficiency.35-38 For 
this purpose, Cy3 labelled BB nanogel was firstly applied to MDA-MB-231 cells to 
monitor their cellular uptake. After 3 hours incubation, we were excited to see significant 
red fluorescence in the nucleus site of the cell, which perfectly colocalize with the nucleus 
stain (Figure 4.8.c). Moreover, the BB functionalized DOX nanogel induced 81% cell death, 
which is much more effective than DOX-nanogel without targeting ligands (Figure 4.8.d).  
 
Figure 4.8. Targeted delivery into nucleus in MDA-MB-231 cells using benzene boronic 
acid functionalized nanogel. a) Functionalization of nanogel with Cy3 and BB; Cellular 
uptake of control nanogel (b) and BB functionalized nanogel (c) after 3 h incubation (red, 
Cy3-nanogel; blue, hoechst; pink, merged two channels. d) Cell viability of empty nanogel 
and DOX loaded nanogel with varied boronic acid content from 0 to 100% (eq. per PEG ). 
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4.3 Summary 
   To summarize, we have developed a functional self-immolative nanogel system for the 
encapsulation of chemotherapy drugs and the delivery of them into the cytosol and 
subcellular organelles such as nucleus and mitochondria of cancer cells. This approach 
perfectly meets all the requirements of an ideal drug delivery system by the following facts 
(i) it takes very simple steps to prepare; (ii) therapeutic drugs are encapsulated with high 
fidelity, i.e., high loading capacity and high stability (iii) the cargo is non-covalently 
encapsulated without any modification; (iv) guest molecules can be released efficiently in 
response to a target intracellular environment; (v) triggered polymer self-immolation 
transforms the polymer from being amphiphilic to completely hydrophilic, which favors 
the complete drug release; (vi) the nanogels can be easily and independently functionalized 
with targeting ligands at the surface; and (vi) drug loaded nanogel can induce efficient cell 
apoptosis. With all these exciting features installed in one nanogel system that is easy to 
prepare, we believe it will serve as a potent drug delivery platform for a broad range of 
small molecules and hold great potential for translational clinical research. 
4.4 Experimental Procedures 
4.4.1. General Methods  
All the reagents were from commercial source and used as received. 1H NMR and 13C 
NMR spectra were recorded on a Bruker DPX-400 MHz NMR spectrometer using the 
residual proton resonance of the solvent as the internal standard. All molecules without 
characterization data mentioned below were synthesized through well-established 
synthesis procedures previously reported by our group.39 Molecular weight of the polymers 
was measured by gel permeation chromatography (GPC, Agilent) using a PMMA standard 
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with a refractive index detector. THF was used as eluent with a flow rate of 1mL/min. UV-
vis absorption spectra were obtained by a Carry 100 Scan spectrometer. Fluorescence 
spectra were recorded on a PerkinElmer LS 55 spectrofluorimeter. Dynamic Light 
Scattering (DLS) data were recorded by a Malvern Nanozetasizer ZS90 with a 637-nm 
laser source with non-invasive backscattering technology detected at 173o using disposable 
sizing cuvette. For Transmission Electron Microscope (TEM) Study: The same sample for 
DLS measurement was dropped onto carbon-coated copper grid. The grid was dried by 
slow evaporation in air, and then dry separately in a vacuum overnight. Images were 
recorded on a JEOL-2000FX electron microscopy operated at 200 kV and at a nominal 
magnification of 5000X. At least 10 locations on the TEM grid were examined.  
4.4.2. Polymer synthesis 
Synthesis of monomer 1: 2-hydroxylethylmathacrylate (1.3 g, 0.01 mol) was dissolved in 
dry THF and then phosgene (15% wt in toluene) (1 eq. ) was added dropwise and kept at 
room temperature for 3 hours, solvent was removed and then redissolved in 
dichloromethane under ice bath, a mixture of triethylamine (2.02 g, 0.02 mol) and 2-
Scheme 4.2 Synthesis route for polymer P1 
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hydroxylethyl-2-pyridyl disulfide (1.87 g, 0.01mol) in DCM was added dropwise, the 
reaction mixture was then stirred at room temperature overnight. Solvent was removed and 
redissolved in ethylacetate, the organic phase was then washed by NaHCO3 solution and 
brine. The organic layer was then evaporated to dryness and purified by silica gel column 
chromatography (0-30% ethyl acetate in hexanes) to afford 2.3 g (67% yield) of 1. 1H NMR 
(400 MHz, CDCl3) δ 8.47-8.49 (d, J = 8 Hz, 7.6 Hz, 2H), δ 7.61-7.68 (m, 2H), δ 7.08-7.12 
(m, 1H), δ 6.14 (s, 1H), δ 5.60 (s, 1H), δ 4.37-4.43 (m, 4H), δ 3.06-3.10 (t, J = 6.6 Hz, 2H), 
δ 1.94 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 167.2, 159.6, 154.8, 149.9, 137.1, 135.9, 
126.4, 121.1, 120.1, 65.9, 65.7, 62.4, 37.1, 18.4. ESI-MS (expected: [m+H]+= 344.0548, 
obtained: [m+Na]+= 366.0685) 
Synthesis of chain transfer reagent (PEG5000-cta) : To a solution of O-(2-Aminoethyl)-
O′-[2-(Boc-amino)ethyl]decaethylene glycol (0.5 g, 0.1 mmol) and triethylamine (0.0612 
g, 0.6 mmol) in DCM was added 4-Cyano-4-(phenylcarbonothioylthio)pentanoic acid N-
succinimidyl ester (0.18 g, 0.5 mmol) solution, the mixture was kept stirring overnight at 
room temperature. Solvent was removed then dialyzed against DCM/MeOH to get purified 
PEG-CTA. (0.51 g, 94% yield). 1H NMR (400 MHz, CDCl3) δ 7.89-7.91 (d, J = 8.0 Hz 
1H), δ 7.54-7.57 (t, J = 7.2 Hz, 7.6 Hz, 1H), δ 7.37-7.41 (t, J = 8 Hz, 7.6 Hz, 2H), δ 6.37 
(s, 1H), δ 5.03 (s, 1H), δ 3.30-3.81 (m, 454H), δ 2.41-2.69 (m,  4H), δ 1.93 (s,  3H), δ 1.43 
(s,  9H). 13C NMR (100 MHz, CDCl3) δ 170.4, 144.6, 132.9, 128.6, 126.7, 118.7, 70.6, 
70.2, 69.7, 50.8, 46.1, 40.6, 39.5, 34.2, 31.6, 28.4,  24.1. GPC (THF): 6.4 kDa, Đ= 1.02. 
Synthesis of polymer P0: A solution of 1 (103 mg, 0.3 mmol), PEG-CTA (150 mg, 0.03  
mmol) and AIBN (0.984 mg, 0.006 mmol), in THF (400 uL) was degassed by three freeze- 
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pump-thaw cycles before being sealed off under argon protection and vaccum. After 6 h at 
65 °C, the polymerization media was diluted in dichloromethane and condensed using 
rotavap, precipitated in diethyl ether for 3 times to remove unreacted monomers. The 
precipitate was collected and dried under vacuum to yield 233 mg (92% yield) of P0. GPC 
(THF): Mn= 9.2 K Da, Đ= 1.02. 1H NMR (400MHz, CDCl3) δ 8.45, 7.66, 7.09, 4.17-4.39, 
3.45-3.81, 3.08, 1.55-1.96, 1.43, 0.85-1.20. 13C NMR (100 MHz, CDCl3) δ 159.4, 154.6, 
149.8, 137.2, 121.0, 119.9, 70.5, 70.2, 65.6, 62.4, 53.4, 36.9, 29.7, 28.4. From 1H NMR, 
integration of f and d provided the molar ratio of PEG/PDS.  
 
Figure 4.9. NMR spectrum of polymer P0 and P1 
Synthesis of polymer P1: P0 was dissolved in DCM/TFA (1mL/1mL) mixture and stirred 
overnight at room temperature. The solvent was evaporated and redissolved in DCM, the 
solution was then dialyzed against DCM/MeOH to get purified P1 (95% yield). GPC (THF): 
Mn= 9.2 K Da, Đ= 1.05. 1H NMR (400MHz, CDCl3) δ 8.50, 7.76, 7.18, 4.18-4.39, 3.45-
3.87, 3.09, 1.75-1.96, 0.85,1.02. 13C NMR (100 MHz, CDCl3) δ 160.0, 159.3, 155.2,150.4, 
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138.5, 138.1, 122.2, 121.8, 120.8, 71.0, 70.6, 66.3, 63.2, 40.8, 37.6, 30.4. Disapperance of 
peak i at 1.43 ppm confirmed the successful deprotection. 
4.4.3 Competition between crosslinking and self-immolation 
Scheme 4.3 Mechanism of crosslinking and self-immolation induced by DTT  
 
4.4.4. Nanogel preparation 
(a) Control nanogel: Deionized water was added to the polymer (5 mg/mL) solution in THF 
(100 uL) and stirred overnight to allow THF to evaporate. Nanogels were achieved by 
chemically cross-linking this equilibrium assembly of the polymer at 25 °C using a 
calculated amount of DTT for 4 h as reducing agent as previously reported.40,41 Cross-
linking was determined by calculating the amount of byproduct 2-pyridinethione using its 
molar extinction coefficient (8.08 × 103 M–1 cm–1 at 343 nm) by UV–vis spectroscopy. The 
size and zeta potential of these nanogel samples were then measured by dynamic light 
scattering at 0.2 mg/ml. 
(b) Guest encapsulation: Polymer solutions in deionized water were stirred at room 
temperature and DiI/PTX/DOX stock solution (15 mg/mL in acetone) was added according 
to designated feeding ratio from 10% to 30%. The solutions were stirred for 8 h in room 
temperature and calculated amount of DTT was then added to crosslink the micelles to 
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generate guest encapsualted nanogel. The solution was then purified by dialysis against 
water for 3 days.  
  Standard curve of DOX was determined using absoprtion at 510 nm of a set DOX samples 
at varied concentration (Figure 4.10.a). The amount of encapsulated DOX in nanogel was 
then calculated from the standard curve. To determine the amount of encapsulated PTX, 
1mg/ml nanogel-PTX solution was first treated with GSH to release the drug, the mixture 
was lyophilized and then redissolved in THF for GPC measurement using the UV detector 
at 220 nm. The loaded PTX amount can be then calculated from the standard curve, which 
was obtained by measuring PTX peak area at different concentrations using GPC (THF). 
(Figure 4.10.b). 
  To achieve the maximum drug loading capacity, we have optimized the crosslinking 
density, drug feeding ratio and polymer hydrophobicity. Nanogel with 20% crosslinking, 
30% drug feeding ratio and PEG:PDS ratio at 1:10 showed the highest drug loading 
capacity, this condition was used for the following cell culture experiments. The 
encapsulation efficiency (EE) and loading capacity (LC) were calculated based on the 
following formulas:  
EE, % = Absorption of loaded drug/absorption of initial feeded drug ×100% 
LC, % = Amount of “encapsulated” drug / amount of polymer ×100% 
(c) Ligands modification: Nanogel formed by P1 can be functionalized with Cy3/folic 
acid/triphenylphosphinium/benzene boronic acid by reacting with corresponding NHS 
ester in PBS buffer pH 8.5, functionalized nanogel was then purified through dialysis 
against deionized water. To vary the ligand density, mix polymer P0 and P1 with calculated 
amount and prepare nanogel following the same protocol as described in a) and b). 
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Figure 4.10. Standard curve of a) DOX based on absorption, b) PTX based on GPC peak 
area. 
 
Figure 4.11. Characterization of ligand decorated nanogels: a) absorption at 345 nm 
suggested folic acid attachment, b) Boronic acid modification shifted the nanogel charge 
from positive to negative; absorption increase at 290 nm (c) and nanogel size increase (d) 
confirmed the Ph3P modification.  
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4.4.5. Cell Culture 
A human breast cancer cell line MDA-MB-231and human liver carcinoma cells Hep G2 
and healthy T293 kidney cell line were grown in DMEM supplemented with 10% (FBS), 
1% l-glutamine, and 1% antibiotic-antimycotic (comprised of 100 units/mL penicillin and 
100 μg/mL of streptomycin). All cells were grown at 5% CO2 and 37 °C. Digestion of cells 
for culture was performed according to protocols from ATCC. 
(a) Cell viability assay: Cells were seeded on flat-bottom 96-well tissue culture plates at a 
density of 5000 cells/well and rested for 24 h at 37 °C in 5% CO2. After overnight 
incubation, the culture medium was removed, and cells were treated with empty or drug 
loaded nanogel samples at different concentrations in complete medium for 48 h. After 
treatments, cells were washed and medium was replaced with 3-(4,5-dimethylthiazol-2-yl) 
2,5-diphenyltetrazolium solution (MTT) (prepared as 0.5 mg/mL in medium) and further 
incubated for 3–4 h at 37 °C. Remove 75 ul of medium and add 50 uL DMSO to each well 
and incubate for another 10 mins. Purple color formation was observed and recorded using 
a plate reader at 540 nm. 
(b) Confocal imaging: Cells were seeded at 30–50% confluency (∼10,400 cells/cm2) in 4-
chamber 35 mm glass bottom dishes and incubated overnight at 37 °C in 5% CO2 before 
performing uptake. Culture media was removed, and cells were washed with PBS one time 
before adding new culture media containing Cy3-labeled nanogels diluted to 0.1 mg/mL in 
DMEM (10× , diluted to 1× with PBS). Samples were incubated for 2 h. Nuclear staining 
(NucBlue, 80 μL/mL of media) and mitotracker green was added in the final 30 min of 
incubation. Medium was removed from cells, which were washed with PBS three times; 
then, live cell imaging buffer was added for confocal imaging. Assessment of Cy3-
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conjugated nanogel intracellular uptake was recorded using 560 nm laser, and nuclear stain 
was detecting using a 405 nm wavelength laser, mitotracker green was detected using a 
488 nm wavelength laser. Confocal microscopy was performed on a Nikon Yokogawa 
spinning disk confocal microscope equipped with 40× oil or 60× oil objectives and an 
Andor EMCCD camera. Co-localization of blue (hoechst) and red (cy5) channels was 
studied to check the nuclei of cells. 
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CHAPTER 5 
 CELL REGULATED NANOGEL ACCUMULATION IN TARGET CELLS 
 
5.1 Introduction 
Off-target accumulation of nanoparticles, especially for in vivo tumor imaging and 
therapeutics, is one of the major hurdles preventing nanoparticles from being successfully 
translated and commercialized for biomedical application. Thus, tremendous efforts have 
been taken to develop the capability of on-target accumulation. These attempts mainly 
focus on optimizing the so-called enhanced permeation and retention (EPR) effect and on 
introducing ligand-receptor interactions for active targeting. Though certain nanoscopic 
objects seem to have the capability of enhancing accumulation in tumor tissues due to EPR 
effect, attributed to defective tumor vasculature and impaired lymphatic drainage, their 
effectiveness in nanomedicine is significantly impeded by the inherent heterogeneity of 
tumors.1-6 Alternatively, active targeting where complementary ligands are incorporated 
onto nanocarriers to recognize receptors overexpressed in tumor cells has been explored 
for selective tumor localization.7-10 However, presence of low level of receptors in off-
target locations can still accumulate ligand-decorated nanocarriers, which gives poor 
selectivity gain and hampers the efficacy of active targeting in vivo.  
To enhance the selectivity of active targeting, ligand masking strategies in which 
ligands are masked and availabilities are only revealed in response to disease 
microenvironment until they reach targets have been developed. But current strategies 
developed for ligand unmasking are primarily focused on using secondary imbalances in 
disease including escalated acidity, redox potential and external stimuli such as ultraviolet 
light that does not have the penetration depth to be useful.11-17 A more effective approach 
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involves the primary imbalance in the disease microenvironments - enzymes to trigger 
ligand exposure.18-23 Past approaches in this regard involves noncovalent, steric protection 
of ligand with enzyme-cleavable bulky groups (e.g. PEG) that decrease the accessibility of 
ligand to bind with receptors.  These approaches require extensive engineering but also 
have limited targeting capability due to the slow cleavage kinetics. 
Here, we propose a cellular AND gate to utilize cell itself to regulate cell-nanoparticle 
interactions and achieve highly selective targeting (Figure 5.1). Alkali phosphatase (ALP) 
and carbonic anhydrase IX (CA IX) are two disease-relevant enzymes overexpressed on 
cell surface.24-27 Nanogels are firstly designed in such a way that they will only accumulate 
in specific disease cells which overexpress both these two types of enzyme, which is termed 
as ‘single cellular AND gate’. If each enzyme is presented on different cell type, the uptake 
of nanoparticles into the CA IX overexpressed cells could be greatly promoted by cells 
overexpress ALP which could reveal the cell interactive functionalities on the nanoparticles, 
this is termed as ‘intercellular AND gate’ (Figure 5.2). Since enzymes are considered to be 
the primary cause of pathological imbalances in biology, these dual enzymes based cellular 
AND gated nanoparticle uptake would open up more possibilities for tumor imaging, 
diagnosis and targeted delivery.  
 
Figure 5.1 Schematic representation of single cellular AND gated nanogel uptake 
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Figure 5.2 Schematic representation of intercellular AND gated nanogel uptake 
5.2 Results and discussion 
5.2.1 Design and synthesis 
Our molecular design involves covalently mask binding motif for CA IX on nanogel 
with alkaline phosphatase (ALP) substrates through a self-immolative linkage to suppress 
nanoparticle cell interaction and cellular accumulation. Since cell membrane interactive 
functionalities are covalently masked, their availability for cell interaction will be 
completely eliminated. We hypothesize that ALP overexpressed cells will cleave the 
readily accessible substrate on nanogel surface to rapidly liberate the sulphonamide ligands 
for interaction with CA IX overexpressed cells. Thus, concurrent presence of ALP and CA 
IX on one cell type would generate a cellular AND gate to achieve specific and rapid 
cellular accumulation.  
The molecular design strategy is shown in Fig. 5.3.  The nanogels will be synthesized 
from a block copolymer that is composed of three components, crosslinkable hydrophobic 
coumarin methacrylate block, a polyethylene glycol block providing hydrophilicity to 
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drive the self-assembly of nanogel, and a phenylsulphonamide, masked with a self-
immolative phosphate substrate, was attached to chain end of the block polymer backbone. 
 
Figure 5.3 Chemical structures of polymeric nanogel and ALP induced exposure of 
sulfonamide ligands 
 
5.2.2 Nanogel preparation and characterization 
    Due to the amphiphilic nature of polymer P2, we attempted to prepare nanoassemblies 
by distributing P2 in water. The nanoassembly formed was found to have an apparent 
hydrodynamic diameter of >120 nm (Figure 5.4) using dynamic light scattering (DLS). 
The hydrophobic core of the nanoassembly was constituted of coumarin moieties, which 
are known to dimerize under UV irradiation (>350 nm).28-29 When expose the 
nanoassemblies to UV light, dimerization of coumarin would crosslink the hydrophobic 
interior and stabilize the nanoassemblies to generate nanogels. Decrease of UV absorption 
of coumarin moieties supported this crosslinking process (Figure 5.4c). Crosslinking 
density can be easily tuned by varying the time of UV exposure. We also noticed that the 
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crosslinked nanogel have a similar size to the nanoassemblies before crosslinking (Figure 
5.4 b). 
 
Figure 5.4 a) Preparation of nanogel; b) DLS profile of micelle and crosslinked nanogel; 
c) UV induced crosslinking of micelles. 
 
5.2.3 Competitive binding assay 
  Our design hypothesis is that the polymeric nanogel will not be capable of binding to 
target enzyme carbonic anhydrase until the presence of ALP covalently cleave the 
phosphotase mask to reveal the sulfonamide ligands. To test this hypothesis, we tested 
whether proposed nanogel as the ligands can bind to bCA using a competitive displacement 
assay where 5-(Dimethylamino)-1-naphthalenesulfonamide (DNSA) is used as the initial 
ligand, the fluorescence emission at 460 nm formed by DNSA-bCA complex indicates 
whether DNSA is replaced (Figure 5.5a). Our studies showed that when the ligands on the 
nanogel were masked by the phosphate moiety, it did not competitively remove DNSA, 
suggested by the little change of fluorescence intensity before and after nanogel was added. 
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However, when added ALP to this system, significant fluorescent signal decrease was 
observed over 30 minutes, indicating the unmasked nanogel was able to displace DNSA 
(Figure 5.5b).  
   
Figure 5.5 a) Schematic representation of competitive binding assay; b) Emission spectrum 
of DNSA-bCA complex after treating with nanogel and ALP. 
 
5.2.4 Intracelluar uptake of nanogels gated by ALP and CA9 in SAOS-2 cells 
  Following this exciting finding, we then want to further test this nanogel system in vitro. 
SAOS-2 is a human osteosarcoma cell line which overexpresses both ALP and CA9. We 
designed a set of experiments listed in table 5.1, by treating the SAOS-2 cells with ALP 
inhibitor or CA9 inhibitor or the combination of these two, we are able to design 
experiments to test whether the cellular uptake of the designed nanogels follows the AND 
gate.  
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Table 5.1. Experimental variations to create AND gated conditons 
SAOS-2 cell line Treated with ALP inhibitor 
Treated with CA9 
inhibitor 
a ✅ ❎ 
b ❎ ✅ 
c ✅ ✅ 
d ❎ ❎ 
	
 
Figure 5.6 a) Flow cytometry histograms of SAOS-2 cells (with/without inhibitor treatment) 
after 2 hours incubation with DiI loaded nanogels, b) statistic data showing the DiI loaded 
nanogel accumulation in SAOS-2 cells. 
 
We hypothesized that SAOS-2 cells treated with either one of the enzyme inhibitors or the 
combination of these two would not uptake the nanogels efficiently, only the control cells 
without any inhibitor treatments would be observed significant nanogel accumulation. To 
test this hypothesis, we loaded the nanogel with a hydrophobic dye, 1,1'-dioctadecyl-
3,3,3'3'-tetramethyl-indocarbocyanine perchlorate (DiI), to track and quantify the cellular 
uptake using flow cytometry and confocal laser scanning microscopy. We were excited to 
find that nanogel accumulation in non-treated cells is significantly higher than cells treated 
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with either ALP or CA IX inhibitors (Figure 5.6). These findings supported our hypothesis 
that ALP and CA IX need to be concurrently present for the nanogels to be uptaken 
efficiently.  
  We are then excited to evaluate the selectivity of nanogels over four different cell lines. 
If proposed AND gate mechanism is operating in this case, the accumulation of nanogels 
will be only observed in the human osteosarcoma Saos-2 cells, where ALP and CA9 are 
concurrently overexpressed. The absence of either protein expression in the other cell lines 
will suppress the accumulation of nanogels. This possibility was tested using Saos-2 
(ALP+, CA9+), MDA-MB-231(ALP+, CA9-), HT-1080 (ALP-, CA9+) and MCF-7 (ALP-, 
CA9-) cell lines. Indeed, DiI loaded nanogels are readily taken up by SAOS-2 (ALP+, CA+) 
cells, but not by MDA-MB-231 (ALP+), MCF-7 (ALP-, CA-), or HT-1080 (CA+) cells, 
as shown in Figure 5.7.  
Figure 5.7 a) Flow cytometry histograms of SAOS-2 cells, MCF-7, HT1080, MDA-MB-
231 cells after 2 hours incubation with DiI loaded nanogels, b) statistic data showing the 
DiI loaded nanogel accumulation in four cell lines. 
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5.2.5 Enhanced nanogel cellular uptake regulated by a second cell line 
   Membrane vesicle trafficking plays an important role in intercellular communication so 
that multitypes of cells could work together to maintain the biofunctions. Inspired by this, 
we have tried to coculture HT-1080 (CA+) and MDA-MB-231 (ALP+) cells and then 
incubated with DiI loaded nanogels. Although these assemblies do not readily enter HT-
1080 (CA+) cells or  MDA-MB-231 (ALP+) cells when they were cultured separately, we 
have observed a significant nanogel accumulation in HT-1080 (CA+) cells when they are 
cocultured with MDA-MB-231 (ALP+), where the cell surface ALP in the latter cell line 
processes the nanogels to be taken up by the former cells after binding to the carbonic 
anhydrase. These results were displayed in Figure 5.8. 
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Figure 5.8 Flow cytometry dual fluorescence density plot histograms of HT1080 and 
MDA-MB-231 coculture (nanogel was loaded with DiI dye, one of the cell lines was 
stained with membrite dye), a) MDA-MB-231 and stained HT1080, b) Histogram of 
nanogel uptake in these two cell lines, c) MDA-MB-231 and stained HT1080 coculture, d) 
Histogram of nanogel uptake in two cell lines. 
5.3 Summary 
  In summary, we have demonstrated a set of cellular logic gates that exhibit efficient 
nanogel uptake in target cells in the presence of two different proteins. Stable nanogels 
with dye loading property have been designed and utilized to evaluate the cellular logic 
gates. We outline molecular designs that can be uptaken selectively by SAOS-2 cells 
overexpress both ALP and CA IX, as well as enhanced uptake in HT1080 cells promoted 
by cocultured MDA-MB-231 cells. The nanogel system was developed by caging a 
carbonic anhydrase-specific ligand with an ALP cleavable phosphate group that masks the 
ligand from being available for protein binding and following cellular accumulation. For 
the programmed single cellular AND gate, it requires the concurrent presence of both ALP 
and CA IX for selective accumulatin only in SAOS-2 cells. Enhanced nanogel uptake into 
HT1080 cells was further promoted by cocultured MDA-MB-231 cells following the 
intercellular AND gate where MDA-MB-231 cells firstly process the nanogels by 
romoving the phosphate mask and reveal the ligands so that they can bind with CA IX in 
HT1080 cells and get uptaken. The design insights and the concept of cellular AND gates 
provided here will find use in the design of novel protein-responsive drug delivery and 
highly selective tumor imaging. 
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5.4 Experimental 
5.4.1 General Methods  
All the reagents were from commercial source and used as received. 1H NMR and 13C 
NMR spectra were recorded on a Bruker DPX-400 MHz NMR spectrometer using the 
residual proton resonance of the solvent as the internal standard. Molecular weight of the 
polymers was measured by gel permeation chromatography (GPC, Agilent) using a PMMA 
standard with a refractive index detector. THF was used as eluent with a flow rate of 
1mL/min. UV-vis absorption spectra were obtained by a Carry 100 Scan spectrometer. 
Fluorescence spectra were recorded on a PerkinElmer LS 55 spectrofluorimeter. Dynamic 
Light Scattering (DLS) data were recorded by a Malvern Nanozetasizer ZS90 with a 637-
nm laser source with non-invasive backscattering technology detected at 173o using 
disposable sizing cuvette. For Transmission Electron Microscope (TEM) Study: The same 
sample for DLS measurement was dropped onto carbon-coated copper grid. The grid was 
dried by slow evaporation in air, and then dry separately in a vacuum overnight. Images 
were recorded on a JEOL-2000FX electron microscopy operated at 200 kV and at a 
nominal magnification of 5000X. At least 10 locations on the TEM grid were examined.  
5.4.2  Polymer synthesis  
Synthesis of L0: small molecule a and b were synthesized according to previously reported 
procedures. Molecule a  (298 mg, 1 mmol) was dissolved in dry THF at 0 oC and then 
molecule b (536 mg, 1.2 mmol)  and triethylamine ( 203 mg, 2 mmol) was added dropwise 
and kept at room temperature for 8 hours, solvent was removed and then redissolved in 20 
mL dichloromethane, the organic phase was then washed by brine (3*30 mL). The organic 
layer was then evaporated to dryness and purified by silica gel column chromatography (0-
  
 
98 
30% ethyl acetate in hexanes) to afford 318 mg (45 % yield) of L0. 1H NMR (400 MHz, 
CDCl3) δ 8.21-8.19 (d, J = 8.8 Hz, 2H), δ 8.12-8.10 (d, J = 8.4 Hz, 2H), δ 7.32 (m, 10H), 
δ 7.17-7.15 (d, J = 8.4 Hz, 2H), δ 5.12-5.10 (d, J = 8.4 Hz, 4H), δ 5.02 (s, 2H), δ 2.9 (s, 
4H). ESI-MS (expected: [m+H]+= 709.1179, obtained: [m+Na]+= 731.6345) 
Scheme 5.1 synthesis route for phosphate ligand and target polymer 
 
Synthesis of L1: Molecule L0  (300 mg, 1 mmol) was dissolved in anhydrous 
dicholoromethane at 0 oC under argon protection and then TMSBr (130 mg, 2 mmol) was 
added dropwise and kept at room temperature for 1 hour, 2 drops of water was added to 
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the reaction mixture and let it stir for another two hours, white precipate was collected 
through filtration and washed three times with cold DCM. The prodcut was collected as 
white powder and generated 201 mg (90 % yield) of L0. 1H NMR (400 MHz, CDCl3) δ 
8.33-8.31 (d, J = 8 Hz, 2H), δ 8.18-8.16 (d, J = 8.4 Hz, 2H), δ 7.32-7.30 (d, J = 8.4 Hz, 
2H), δ 7.21-7.19 (d, J = 8.4 Hz, 2H), δ 5.07 (s, 2H), δ 2.94 (s, 4H). ESI-MS (expected: 
[m+H]+= 529.0240, obtained: [m+Na]+= 551.3352) 
Synthesis of P0: A solution of M (103 mg, 0.3 mmol), PEG-CTA (150 mg, 0.03 mmol) 
and AIBN (0.984 mg, 0.006 mmol), in THF (400 uL) was degassed by three freeze-pump-
thaw cycles before being sealed off under argon protection and vaccum. After 6 h at 65 °C, 
the polymerization media was diluted in dichloromethane and condensed using rotavap, 
precipitated in diethyl ether for 3 times to remove unreacted monomers. The precipitate 
was collected and dried under vacuum to yield 233 mg (93% yield) of P0. GPC (THF): 
Mn= 8.8 K Da, Đ= 1.02. 1H NMR (400 MHz, CDCl3) δ 7.45, 6.80, 6.79, 6.07, 3.97, 3.83, 
3.66, 3.48, 2.36, 1.96, 1.82, 1.67, 1.50, 1.46, 1.26, 1.06, 0.89. From 1H NMR, integration 
of peak at δ 6.07 and δ 3.83 provided the molar ratio of PEG/PDS to be 1:10. 
 
Synthesis of polymer P1: P0 was dissolved in DCM/TFA (1mL/1mL) mixture and stirred 
overnight at room temperature. The solvent was evaporated and redissolved in DCM, the 
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solution was then dialyzed against DCM/MeOH to get purified P1 (95% yield). GPC 
(THF): Mn= 8.2 K Da, Đ= 1.05. 1H NMR (400MHz, CDCl3) δ 7.43, 6.78, 6.67, 6.05, 3.95, 
3.81, 3.63, 3.45, 2.34, 1.97, 1.80, 1.66, 1.43, 1.24, 1.04, 0.87. Disapperance of peak i at 
1.50 ppm confirmed the successful deprotection. 
  
Synthesis of polymer P2: P1 (100 mg), triethylamine (5 uL) and ligand L1 (8.8 mg, 10 eq.) 
was dissolved in DCM and stirred overnight at room temperature. The solvent was 
evaporated and redissolved in DCM, the solution was then dialyzed against DCM/MeOH 
to get purified P2 (95% yield). GPC (THF): Mn= 9 K Da, Đ= 1.05. 1H NMR (400MHz, 
CDCl3) δ 8.22-8.15, 7.45-7.41, 6.78, 6.67, 6.05, 5.13, 3.95, 3.81-3.45, 2.92, 2.33, 1.80,  
1.65, 1.45, 1.27, 1.05, 0.87. New peaks at  δ 8.22-8.15, δ 7.45-7.41 and δ 5.13 ppm 
confirmed the ligand modification. 
 
  
 
101 
5.4.3 Nanogel preparation and characterization 
DiI loaded nanogel: Polymer solutions (5 mg/mL) in deionized water were stirred at room 
temperature and DiI stock solution (5 mg/mL in acetone) was added according to 
designated feeding ratio 5 wt%. The solutions were stirred for 8 h in room temperature and 
filtered with 0.45 um PTFE filter to remove unencapsulated dye molecules. Cross-linking 
was done by exposing polymer solutions to UV irradiation (365 nm) for 2 minutes. The 
size of these nanogel samples were then measured by dynamic light scattering at 0.2 mg/ml. 
5.4.4 Cellular uptake 
Human breast cancer cell lines MDA-MB-231 and MCF-7, a fibrosarcoma cell line 
HT1080, a human osteosarcoma cell line SAOS-2 were grown in DMEM supplemented 
with 10% (FBS), 1% l-glutamine, and 1% antibiotic-antimycotic (comprised of 100 
units/mL penicillin and 100 μg/mL of streptomycin). All cells were grown at 5% CO2 and 
37 °C. Digestion of cells for culture was performed according to protocols from ATCC. 
a) Confocal imaging: Cells were seeded at 30–50% confluency in 8-well ibidi chamber 
glass bottom dishes and incubated 12 hours at 37 °C in 5% CO2 before performing 
uptake. Culture media was removed, cells were washed with PBS one time before 
adding new culture media containing DiI loaded nanogels diluted to 0.0375 mg/mL in 
DMEM. Samples were incubated for 1 h. Nuclear staining (NucBlue, 80 μL/mL of 
media) was added in the final 30 min of incubation. Medium was removed from cells, 
which were washed with PBS three times; then, live cell imaging buffer was added for 
confocal imaging. Assessment of nanogel intracellular uptake was recorded using 560 
nm laser, and nuclear stain was detecting using a 405 nm wavelength laser. Confocal 
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microscopy was performed on a Nikon Yokogawa spinning disk confocal microscope 
equipped with 40× oil or 60× oil objectives and an Andor EMCCD camera.  
b) Flow cytometry: For single cellular uptake experiments, each cell type was seeded at 
the following density in a 12-well glass bottom dish and maintained at 37 °C overnight 
in 5% CO2 for 12 hours before performing uptake: MDA-MB-231 at 15K cells/mL, 
HT1080 at 10K cells/mL, MCF-7 at 15K cells/mL, SAOS-2 at 30K cells/mL. Culture 
medium was removed, and cells were washed with PBS one time before adding new 
culture medium containing DiI loaded nanogels diluted to 0.0375 mg/mL in DMEM 
(10Å~ , diluted to 1Å~ with PBS). Samples were incubated for 1h, then washed with 
PBS, trypsinized, and collected by centrifugation. The cells were resuspended in 200 
μL of PBS buffer and stored at 4°C. A minimum of 100,000 cells were analyzed for 
each sample using a BD LSRFortessa. 
For cocultured cellular uptake experiments, coculture of stained MDA-MB-231 and 
unstained HT1080 cells at a seeding ratio of 3:2 were seeded in 6-well glass bottom 
dish for 12 hours and then following same procedures as above. Similar procedures 
also applied to the coculture of unstained MDA-MB-231 and stained HT1080 cells. 
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CHAPTER 6 
 SUPRAMOLECULAR ASSEMBLIES FOR PROTEIN TRANSPORT ACROSS 
SOLVENT INTERFACE 
 
Adapted with permission from Gao, J.; Zhao, B.; Wang, M.; Serrano, M. A. C.; Zhuang, 
J.; Ray, M.; Rotello, V.; Vachet, R. W.; Thayumanavan, S. “Supramolecular Assemblies 
for Transporting Proteins Across an Immiscible Solvent Interface” J. Am. Chem. Soc., 2018, 
140, 2421–2425. Copyright © 2018 American Chemical Society 
 
6.1 Introduction 
Transporting molecules across incompatible interfaces is a significant challenge, 
especially for macromolecules. A striking example of an interfacial barrier is the cellular 
membrane, where an organized presentation of hydrophilic and hydrophobic functional 
groups provides a formidable barrier for molecular transport.1 While small hydrophobic 
molecules can passively transport across this membrane barrier and small ionic molecules 
can be transported through natural or artificial ion channels, globular proteins with large 
hydrophilic surfaces offer no easy access. 2,3 Nonetheless, cells do transport proteins when 
necessary for inter-cellular communication, often using nanoscopic vesicular 
compartments called exosomes.4,5 Inspired by these cell-derived vesicles, we became 
interested in exploring the possibility of transporting proteins into a nanoscopic 
compartment across a solvent interface. While simply transporting proteins across 
interfaces has many implications, selective transport, while retaining structure and function, 
could be transformative in applications such as sensing, delivery, and diagnostics. 
Supramolecular assemblies have already shown great potential in these areas6-8 and 
  
 
107 
supramolecular protein transport would add to this armor. Reverse micelle systems from 
small molecule surfactants have shown the potential to solubilize proteins in organic 
solvent, however, the stability can be easily affected by a lot of factors such as salt and 
pH.9-11 Also, the selectivity of these systems is quite limited. Herein, we report a simple 
supramolecular approach based polymeric platform that selectively transports water-
soluble globular proteins from an aqueous phase to the water-pool of a reverse micelle in 
an apolar organic phase (Figure 6.1). 
We outline two strategies to selectively shuttle protein molecules from an aqueous phase. 
In the first approach, we rely on complementary electrostatic interactions to bind proteins 
in an aqueous phase and ferry them over to the interior of a reverse micelle in an apolar 
solvent such as toluene. In a second approach, we explore the use of specific ligand-protein 
interactions to selectively transport proteins from an aqueous phase into an apolar phase. 
 
Figure 6.1. Schematic representation of reverse micelle driven protein transportation. 
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6.2 Results and discussion 
6.2.1 Molecular design and synthesis 
  For the initial proof-of-concept, we first synthesized a polystyrene-based amphiphilic 
random copolymer P1 (Mn= 11 kDa, Đ=1.09) (Figure 6.2a). This anionic polymer, 
achieved using nitroxide-mediated polymerization, comprises of 40% p-decyloxystyrene 
as the hydrophobic monomer and 60% of p-oxyacetyl-styrene as the hydrophilic monomer. 
A corresponding cationic polymer, P2, was obtained by coupling the carboxylate acid 
moiety in P1 with N,N-dimethylethylenediamine under EDC-coupling conditions, 
followed by quaternization of the tertiary amine with methyl trifluoromethanesulfonate 
(Figure 6.2b).  
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Figure 6.2. Structural features of polymeric reverse micelles. Molecular structure of 
polymer P1 (Mn= 11 kDa, Đ= 1.09) a) and P2 b) (Mn= 12 kDa, Đ= 1.15), c) DLS profile 
of P1 and P2 in toluene, TEM of P1(d) and P2(e). 
 
6.2.2 Reverse micelle preparation and characterization 
  The possibility of these polymers forming a reverse micelle assembly was tested by 
distributing these polymers in toluene along with two equivalents of water per carboxylate 
or quaternary ammonium moiety. The water molecules are added to provide a ‘water pool’ 
for the reverse micelles. Assemblies with a fairly homogeneous size distribution of 50 nm 
for P1 and 37 nm for P2 were observed, as discerned by both dynamic light scattering 
(DLS) (Figure 6.2c) and transmission electron microscopy (TEM) (Figure 6.2d-e).  
6.2.3 Electrostatic interaction driven protein transport 
  The key premise for the work here is that the polymers would self-assemble in apolar 
solvents, bind to complementarily charged proteins in the aqueous phase, and ferry them 
across the interface to the interior of the reverse micelles in toluene. To test this possibility, 
porcine liver esterase (plE, MW = 168 kDa) was used as the model protein, because this 
protein is negatively charged enzyme at pH 8.0 (isoelectric point pI = 5.3). We used reverse 
micelles based on the cationic polymer P2. Upon equilibrating an aqueous solution 
containing plE with a toluene solution containing P2 (1 mg/mL) reverse micelles, the 
presence of proteins in both phases was detected using matrix assisted laser 
desorption/ionization mass spectrometry (MALDI-MS). Figures 6.3a and 6.3b show the  
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Figure 6.3. MALDI-MS analysis of a) aqueous phase before equilibration, b) organic 
phase before equilibration, and c) the organic phase after equilibration. d) Activity of 
esterase (based on substrate cleavage) inside reverse micelles compared with esterase 
activity in bulk aqueous phase. 
mass spectrum of the aqueous and organic phases, respectively, before equilibration. After 
equilibration, we were gratified to observe the presence of a peak corresponding to plE in  
the organic phase (Figure 6.3c), suggesting that plE was successfully transported into 
interior of the reverse micelles.  
  In order to quantify the extent of protein that was encapsulated within the reverse micelles, 
we analyzed the organic phase for proteins using the bicinchoninic acid (BCA) assay. This 
analysis showed that 1 mg of polymer is capable of transporting and binding to 0.05 mg of 
plE, an equivalent of 5 wt% loading capacity. This capacity compares much more favorably  
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Figure 6.4. a) SDS-PAGE for transport and release of plE from reverse micelles; b) 
Intensity value for each band of SDS-PAGE; c) Standard curve of plE based on SDS-PAGE. 
than the typical loading capacity of proteins in liposomes.15 When treated the organic phase 
with THF and acidic solution, we found that the plE can be released into the aqueous phase, 
as shown in the SDS-PAGE analysis of organic phase and aqueous phase before and after 
equilibration (Figure 6.4).  
A more compelling analysis is to identify whether the enzyme molecules, which were 
extracted into the organic phase, remain active. To investigate this possibility, we 
synthesized a substrate for plE that is amenable for use both in organic and aqueous phases 
(Scheme 6.1). If we were to use water-soluble substrates and investigate the activity in the 
reverse micelles using an apolar solvent, we would likely get a solvophobically driven 
concentration increase of the substrate, which could be interpreted as an increase in 
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enzymatic activity in the reverse micelle. Instead, we were interested in truly estimating 
the activity of the enzyme. Therefore, we designed and synthesized an amphiphilic 
coumarin-based profluorophore S1. The alkylated phenolic state of this substrate causes 
this molecule to be non-fluorescent. When the ester bond of S1 is cleaved by the enzyme, 
the resultant hemiacetal rapidly degrades to generate umbelliferone, a fluorescent coumarin 
molecule. 
Scheme 6.1. Substrate cleavage in present of esterase 
 
 
The substrate itself was quite stable in PBS buffer as well as after equilibration with 
toluene solution containing P2. In the presence of plE, however, a rapid hydrolysis of S1 
to generate the fluorescent umbelliferone was observed (Figure 6.3d). We then analyzed 
the possibility of this reaction in toluene in the presence of reverse micelles loaded with 
plE. Interestingly, the hydrolysis rate was found to be quite similar to that of the free 
enzyme. As the estimated concentration of the enzyme inside the reverse micelle and the 
free plE in the aqueous phase in the two experiments above are the same, these results were 
taken to suggest that the activity of plE is maintained inside the reverse micelles. As another 
control experiment, we were interested in finding whether the electrostatic complex 
between P2 and plE has any inherent effects upon the activity of the latter. To test this, we 
mixed plE and P2 in aqueous phase and found that the activity of the enzyme was slightly 
lower, suggesting that interactions between P2 and plE have little effect on plE activity.  
When considering the pathway by which these polymers could transport proteins across 
the interface, two limiting possibilities can be proposed. Note that these polymers can form 
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micelle-like assemblies in the aqueous phase and reverse-micelle-like assemblies in the 
apolar toluene phase. Therefore, it is possible that the polymers equilibrate themselves 
between the two phases. The resultant thermodynamic equilibrium between the two solvent 
phases, combined with the complementary binding affinity to the proteins, cause proteins 
to be extracted to the organic phase. Alternately, the exchange of water molecules between 
the interior of the reverse micelle and the bulk water (in the biphasic mixture) ferry proteins 
into the interior of the reverse micelles. If there is an affinity between the protein and the 
functional groups within the interior of the assembly, then the proteins would stay in the 
reverse micelle. In this latter scenario, the polymer assemblies remain kinetically trapped 
as reverse micelles in the organic phase. To differentiate these two pathways, we 
equilibrated the reverse micelle assemblies of polymers P1 and P2 with water. UV-visible 
absorption spectra of both phases indicate that these polymers fully remain in the apolar 
phase (Figure 6.5). While this suggests that the polymers might be kinetically trapped in 
the organic phase, it is also possible that these polymers thermodynamically prefer the 
apolar phase. To delineate this possibility, these polymers were initially assembled as 
micelles in the aqueous phase and equilibrated with toluene (Figure 6.6). The exclusive 
presence of these polymers in the aqueous phase, this time, shows that these 
supramolecular assemblies are kinetically trapped in the solvent that they are initially 
assembled. Overall, these results suggest protein molecules can exchange between phases, 
but only remain in the apolar phase if they have favorable interactions with the reverse 
micelle interiors. 
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Figure 6.5. UV-Vis measurements with reverse micelles of a) polymer P1 (1 × 10-4 M), b) 
polymer P2 (1 × 10-4 M starting in toluene (ORG), before and after equilibration with 
aqueous phase (AQ). 
 
 
Figure 6.6. UV-Vis measurements with micelles of a) polymer P1 (1 × 10-4 M), b) polymer 
P2 (1 × 10-4 M starting in water (AQ), before and after equilibration with apolar phase 
toluene (ORG). 
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  Following these observations, we were interested in exploring the applicability of this 
approach to other non-enzymatic proteins. Green fluorescent protein (GFP) was used as 
the first model protein, not only because it can be readily monitored using fluorescence, 
but also because the fluorescence itself is a good indicator of whether the protein maintains 
its tertiary structure. Since wild-type GFP (pI 6.2) has a net charge of -7 at pH 7.4, we 
hypothesized that positively-charged reverse micelles from P2 should be able to move GFP 
(-7) from aqueous phase to organic phase. To test this possibility, an aqueous solution of 
GFP was equilibrated with the P2 reverse micelle solution in toluene. We were gratified to 
find that the emission spectrum of the organic phase clearly showed the presence of GFP. 
To further confirm the presence of GFP in the organic phase, samples of both phases were 
analyzed by MALDI-MS and a peak with a m/z ratio of 28,432 Da was indeed observed in 
both phases (Figure 6.7).  
Figure 6.7 MALDI-MS analysis of GFP before and after transportation a) GFP (-7) before 
transportation, b) organic phase after transportation GFP (-7) using P1, c) organic phase 
after transportation GFP (-7) using P2, d) GFP (+15) before transportation, b) organic phase 
after transportation GFP (+15) using P2, c) organic phase after transportation GFP (+15) 
using P1. 
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  Note that the extent of extraction was not optimized to be quantitative, because the 
incomplete extraction provides an important insight into the nature of the GFP inside the 
reverse micelles. The combination of emission intensities in the aqueous and the organic 
phases equal that of the pre-equilibrated emission intensity in the aqueous phase (Figure 
6.8a). This observation suggests that GFP maintains its tertiary structure, responsible for 
the fluorophore preservation in the protein, during the transport process across the solvent 
interface.  To confirm that this transport is indeed due to electrostatic complementarity, a 
control experiment using the anionic reverse micelle from P1 was carried out. Indeed, there 
was no discernible change in the emission intensity of the aqueous phase (Figure 6.8b). 
 
Figure 6.8. Emission spectrum of GFP showing whether it was transported to the organic 
phase, a) GFP (-7) transport by P2, b) GFP (-7) transported by P1, c) GFP (+15) transported 
by P1, d) GFP (+15) transported by P2. 
 
To further test this idea, we utilized cationic GFP protein, the so-called supercharged GFP 
(+15).16 Indeed here, the anionic polymeric reverse micelle from P1 is able to transport the 
protein across the interface, while the cationic reverse micelle from P2 does not affect the 
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protein in the aqueous phase (Figures 6.8c and 6.8d). The results from these studies show 
that: (i) transport of proteins across the interface is due to electrostatic complementarity, 
not due to spurious differences in inherent binding abilities of P1 and P2; (ii) the tertiary 
structure of the proteins can be preserved upon transport across the interface as indicated 
by the roughly equal emission intensities before and after equilibration; (iii) at similar 
polymer and protein concentrations, the extent of protein extraction in GFP (+15) is 
considerably higher than GFP (-7), showing that binding affinity can influence the extent 
of proteins transported across the interface.  
6.2.4 Protein transport driven by ligand-protein binding 
While electrostatic complementarity can be utilized to simplify protein mixtures and 
enable identification of the presence of specific proteins, this ability will be even more 
greatly enhanced if proteins can be transported across an interface in response to a specific 
ligand-protein interaction. To investigate this possibility, we used bovine carbonic 
anhydrase (bCA) as the model protein, because aryl sulfonamides are well-established as 
small molecule ligands for this protein.15,18 The design hypothesis here is that if this ligand 
was installed in the polymeric reverse micelles, it should be able to selectively transport 
bCA to the organic phase due to specific binding.  
  We designed a zwitterionic amphiphilic polymer for this purpose, as the charge-neutral 
zwitterionic polymer avoids any electrostatics-based non-specific interactions. 
Accordingly, a random copolymer P3 (Figure 6.9a), containing 40% decyl chain as the 
hydrophobic moiety, 40% zwitterionic sulphobetain group as the hydrophilic moiety and 
20% benzene sulfonamide as the ligand moiety, was prepared through post-modification 
of polymer P1. P3 forms a similarly sized assembly in apolar solvents. To test the capability 
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of P3 in transporting proteins, we first labeled bCA with tetramethylrhodamine-5-
isothiocyanate (TRITC) to monitor the location of proteins using fluorescence. Indeed, 
after equilibration of an aqueous phase containing TRITC-bCA with the organic phase 
containing P3 micelles, we observed a strong emission peak in organic phase, indicating 
the transportation of TRITC-bCA conjugates. Concurrently, there is a dramatic decrease in 
the fluorescence intensity in the aqueous phase, indicating bCA is successfully transported 
across the interface.  
To investigate whether this is driven by the ligand-protein binding, we designed a control 
experiment in which a structurally similar amphiphilic polymer, P4, which forms reverse 
micelles but lacks the sulfonamide functional group, was equilibrated with an aqueous 
solution containing TRITC-bCA.  No change is observed in the emission spectrum of both 
organic and aqueous phases, when using P4 as the transporter (Figure 6.9b). To further test 
whether the specific ligand-protein interaction is responsible for the observed transport 
across the interface, we designed another control experiment. For a ligand to bind to the 
active site of the protein, the structural integrity of the protein must be maintained. Before 
attempting to transport the protein, we disrupted the structure of the protein by denaturing 
the protein with acetonitrile and heat. The denatured bCA should not be able to bind the 
sulfonamide ligands and thus would not be transported into the organic phase. Indeed, we 
find that no fluorescence changes in the aqueous or organic phase are observed, showing 
that no bCA was transported into the organic phase (Figure 6.9b). These results confirm 
that transportation occurs only when bCA’s native structure is maintained in such a way to 
preserve its ability to bind the sulfonamide ligand. Overall, these results suggest that 
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specific ligand-protein interactions can be utilized to bind and transport proteins across the 
solvent interface.  
	
Figure 6.9. a) Molecular structure of P3, b) Fluorescence change of aqueous/organic phase 
using P3 or P4 to transport bCA, c) Molecular structure of P4, d) Fluorescence change of 
aqueous/organic phase of P3 to transport bCA, Myb or Lyz, e) MALDI-MS analysis of 
protein mixture before and after transportation. 
 
  Next, to test the ligand-protein binding based selectivity associated with this process, we 
performed another set of control experiments using myoglobin (Mb) and fluorescently 
labelled lysozyme (Lyz). Myoglobin was chosen because it has absorption at 409 nm, while 
lysozyme was labelled as TRITC-lysozyme conjugates, in order to independently monitor 
the movement of these proteins by fluorescence change. Since benzene sulfonamide 
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ligands have little to no binding affinity to these proteins, we predicted that Mb and Lyz 
would remain in the aqueous phase. Indeed, no discernible fluorescence change was 
observed in both aqueous and organic phases for these two proteins, suggesting that the 
ligand attached reverse micelles are specific for the target protein bCA (Figure 6.9d). These 
experiments were initially done separately due to the possible bleeding of fluorescence 
emission. Selective transport from a mixture of these proteins was tested using MS. In this 
experiment, Mb, Lyz and bCA were prepared as a protein mixture at the same concentration, 
and then P3 was used to transport bCA from the aqueous phase to the organic phase. We 
were gratified to find that only bCA is transported to the organic phase, while Mb and Lyz 
remained in the aqueous phase as indicated by the mass spectra before and after 
equilibration (Figure 6.9e). These data strongly support the idea that ligand-attached 
reverse micelle systems are specific for target proteins. 
 
Figure 6.10. Increase in the ligand intensity (z value) can transport more bCA from aqueous 
phase to organic phase. 
 
6.3 Summary 
In conclusion, we have demonstrated a set of supramolecular assemblies, based on 
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amphiphilic polymers, that can transport proteins across a solvent interface. We have 
shown here that: (i) simple electrostatic complementarity in polymeric reverse micelle 
systems can transport proteins from bulk aqueous phase into the interior of a reverse 
micelle assembly in the apolar organic phase; (ii) the activity of the transported proteins is 
retained in the process; (iii) the efficiency of protein binding is dependent on the charge 
density presented on the protein surface; (iv) the kinetically trapped nature of the 
assemblies suggest that the polymers do not ferry the proteins but instead transport likely 
occurs during the solvent exchange within the interior of the assembly, when these 
assemblies transiently find themselves at the aqueous/organic phase interface during 
equilibration, as illustrated in Figure 6.1; (v) specific ligand-receptor interactions can be 
used to selectively extract proteins from the aqueous phase. Overall, the most gratifying 
finding here is that whole proteins can be moved across a solvent interface into the interior 
of a supramolecular assembly, even though the resident location of the assembly is in an 
incompatible solvent for the protein. The preliminary findings here have implications in 
many areas, especially in sensing, diagnostics, and catalysis. For example, these systems 
can be further developed to detect biomarkers in more complex mixtures of proteins.17-23 
Similarly, facile incorporation of active proteins in organic solvents could facilitate 
enzyme-based catalysis for a broader range of organic substrates.24-29 These constitute 
examples of future directions for this research in our own laboratories. 
6.4 Experimental procedures 
6.4.1 General methods 
All reagents were commercially available and used as received unless stated otherwise. 1H-
NMR spectra were recorded on a 400 MHz or a 500 MHz NMR spectrometer using residual 
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proton resonance of the solvents as internal standard. Chemical shifts are reported in parts 
per million (ppm). Mass spectra were obtained by a Bruker AmaZon quadrupole ion trap 
mass spectrometer coupled with electrospray ionization source. Gel permeation 
chromatography (GPC) was used to estimate the molecular weight of polymers using 
THF/DMF as eluent and 1 μL of toluene was added as the internal reference. Polystyrene 
standards were used for calibration and data analysis.  
For the DLS measurements, the polymers were dissolved in toluene, and one equivalent of 
water per hydrophilic unit was added to form the water pool inside the reverse micelles. 
The samples were sonicated until clear solutions were formed. DLS measurements were 
carried out in a quartz cuvette at room temperature. The sizes of each solution were 
recorded overtime by a Malvern Nanozetasizer ZS90 with a 637-nm laser source with non-
invasive backscattering technology detected at 173o using quartz cuvette. Standard 
operating procedures (SOP) are set up including following parameters: the sample was 
equilibrated for 120 s at 25 oC before each measurement; the sizes were reported as the 
hydrodynamic diameter (DH) and each measurement average 16 runs were repeated three 
times.  
For TEM measurement, the same sample for DLS measurement was dropped onto carbon-
coated copper grid. The grid was dried by slow evaporation in air, and then dry separately 
in a vacuum overnight. Images were recorded on a JEOL-2000FX electron microscopy 
operated at 200 kV and at a nominal magnification of 5000X. At least 10 locations on the 
TEM grid were examined. The assembly diameter was calculated using ImageJ software. 
Matrix Assisted Laser Desorption/Ionization Mass Spectrometry (MALDI-MS): MALDI-
MS analysis of samples before and after transport were performed with Bruker Autoflex 
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III time-of-flight mass spectrometer. The matrix was prepared with a solvent mixture of 
acetonitrile, water and trifluoroacetic acid (with a ratio 50:47.5:2.5) containing 10 mg/mL 
sinapic acid. The matrix and samples from aqueous or organic phase were mixed at 1:1 
ratio and spotted on the MALDI target for analysis.  
Protein transport and release experiments: For protein transport with reverse micelles, 500 
uL of a toluene solution of polymers (1 mg/mL) with 1 mL of protein in 10 mM PBS buffer 
at pH 7.4. The mixture is vortexed for 30 min and centrifuged at 10,000 rpm for 1 h to 
separate the organic and aqueous layers. The organic phase and aqueous phase is then 
analyzed by MALDI-MS or fluorimeter.  
For the release of proteins back into the aqueous phase, the 500 uL organic phase contains 
proteins was treated with 100 uL THF and then equilibrated with 400 uL 1 M HCl for 30 
minutes. After centrifugation for 30 minutes, the phase was separated. The pH of aqueous 
phase was adjusted to 7.4 for further analysis. 
Quantification of porcine liver esterase in reverse micelles: 1) Through the BCA method: 
The standard curve was made using Pierce BCA assay kitS3 as following the protocols. 
Pipette 0.1 mL of each standard sample (0.005, 0.025, 0.05, 0.125, 0.25, mg/mL, three 
replicates for each sample) and the unknown plE sample into test tube and then add 2.0 mL 
of the working reagent to each tube and mix well. Cover and incubate tubes at 60 oC for 30 
minutes and then cooled to room temperature. Then took the readings from UV-Vis at 562 
nm. The standard curve was prepared plotting the average 562 nm measurement for each 
standard sample vs. its concentration. Then the plE concentration of aqueous phase after 
transport was determined using the standard curve. The difference of aqueous phase before 
and after the equilibration provide the loading capacity of reverse micelles.  
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2) Through SDS-PAGE method: Standard curves were generated from the known 
concentrations of protein samples loaded into the gel lanes. Then the samples of aqueous 
phase before and after the equilibration were loaded to the gel lane. For the organic phase, 
the samples for gel lanes were dried with air and dissolved in THF/H2O. The intensities for 
the band will be used to calculate the protein concentration of each phase. The 
concentration of protein for the organic phase after equilibration can provide how much 
proteins have been transported into the organic phase.  
SDS-PAGE Analysis: For the transport and release of plE studies: 20 µL of different 
samples containing plE were mixed with 20 µL of loading buffer (3% DTT), then incubated 
95 ºC for 10 minutes before subjecting 10 µL of each sample to acrylamide gel 
electrophoresis. Standard curves were generated from the known concentrations of pure 
protein samples loaded into the gel lanes. The gel image analysis and quantification were 
performed with Bio-Rad Image LabTM software. 
Evaluation of PlE activity in reverse micelles: First, the amount of plE that got transported 
into the organic phase was calculated based on the SDS-PAGE or BCA assay. The organic 
phase containing plE was then equilibrated with an aqueous phase of substrate S1 (100 µM) 
for 30 minutes. After centrifugation for 30 minutes, the fluorescence of aqueous phase was 
measured over time. The control experiments with the same amount of plE were performed 
in aqueous phase. 
Protein denaturation: bCA was dissolved in 10 mM PBS (pH 7.4) buffer at a concentration 
of 1mg/mL, 10% by volume of acetonitrile was added to the solution and stirred at room 
temperature for 10 minutes. After that, the mixture was heated at 100oC for 2 minutes and 
then a buffer exchange was performed using 3 k Da Amicon Ultra Centrifugal Filters to 
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remove acetonitrile. Then the sample was diluted to 0.1 mg/mL in 10 mM PBS (pH 7.4) 
for CD measurement. 
Circular dichroism (CD) spectra: CD spectra bCA and denatured bCA were recorded on 
JASCO J-1500 spectrophotometer. For recording the spectra, 200 µL 0.1 mg/mL protein 
solution was injected into a quartz cuvette of 1-mm path length, equilibrated at 25 ºC for 
10 min and scanned from 190 to 250 nm (scan rate: 20 nm/min, interval: 0.2 nm, average 
of three spectra). 
Fluorescent labeling proteins: Labeling of proteins (lysozyme (Lyz), bovine serum albumin 
(BSA) and bovine carbonic anhydrase (bCA)) with Tetramethylrhodamine-5-
Isothiocyanate (TRITC) or Fluorescein Isothiocyanate (FITC). In a typical labelling 
procedure, proteins (4 mg) were dissolved separately in 2 mL of 0.1 M NaHCO3 buffer 
(pH 8.5) and stirred for 15 min at 4 ºC. TRITC/FITC (5 eq. of each protein, 10 mg/mL in 
DMSO) was added dropwise to each protein solution and stirred at 4 ºC for 2 h protected 
from light. The labelled-proteins were purified by extensive dialysis with 50 mM PBS pH 
7.4 and 50 mM NaCl mixture to remove excess dye and concentrated using 3 kDa Amicon 
Ultra Centrifugal Filters. Protein concentrations in each labelled conjugate were calculated 
using UV-Vis spectroscopy. 
6.4.2 Polymer synthesis 
Synthesis of compound 1: According to previous procedureS1, to a solution of acetone 
mixed with K2CO3 (11.84 g, 85.65 mmol) and 18-crown-6 (1.13 g, 4.28 mmol), 4-
hydroxybenzaldehyde (5.23 g, 42.83 mmol) was added and stirred for 5 min. To this 
mixture, 1-bromodecane (14.21 g, 64.24 mmol) was added and stirred while refluxing for 
20 h. The reaction mixture was then cooled to room temperature and filtered to afford the 
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crude product in acetone solution. The solvent was evaporated to dryness and purified by 
silica gel column chromatography (8-10% ethyl acetate in hexanes) to obtain 8.8 g (79% 
yield) of 1. 1H NMR (400 MHz, CDCl3) δ 9.80 (s, 1H), δ 7.83-7.81 (d, J = 8.0 Hz, 2H), δ 
7.00-6.98 (d, J = 8.0 Hz, 2H), δ 4.02-4.05 (t, J = 6.6 Hz, 2H), δ 1.76-1.83 (quint, 2H), δ 
1.47-1.26 (m, 14H), δ 0.87-0.91 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 190.7, 
164.2, 131.9, 129.7, 114.7, 68.4, 31.9, 29.5, 29.63, 29.32, 29.31, 29.1, 25.9, 22.7, 14.1. 
ESI-MS (expected: [m+H]+= 263.19, obtained: [m+Na]+= 285.2) 
Scheme 6.2. Synthetic route for polymer P1 
 
 
Synthesis of compound 2: Methyltriphenylphosphonium bromide (6.58 g, 25.11 mmol) 
and potassium tert-butoxide (3.94 g, 35.15 mmol) were mixed in a round bottom flask, and 
dry THF (20 mL) was added to the mixture. The mixture was stirred under argon 
atmosphere in an ice bath for 15 min to yield a bright yellow solution. 1 (6.58 g, 25.11 
mmol) was slowly added to the mixture. The reaction mixture was further stirred for 5 h. 
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After the reaction, saline and ethyl acetate were added for extraction. The combined 
organic layer was separated and washed with saline (3 times). The organic layer was 
evaporated to dryness and purified by silica gel column chromatography (3-5% ethyl 
acetate in hexanes) to afford 5.7 g (88% yield) of 2. 1H NMR (400 MHz, CDCl3) δ 7.31-
7.33 (d, J = 8.0 Hz, 2H), δ 6.83-6.85 (d, J = 3.4 Hz, 2H), δ 6.61-6.68 (q, 1H), δ 5.57-5.61 
(d, J = 7.2 Hz,  1H), δ 5.09-5.12 (d, J = 4.4 Hz,  1H), δ 3.93-3.96 (t, J = 5.4 Hz,  3H), δ 
1.73-1.80 (quint, 2H), δ 1.27-1.46 (m, 14H), δ 0.86-0.89 (t, J = 6.8 Hz, 3H). 13C NMR (125 
MHz, CDCl3) δ 159.1, 136.4, 130.3, 127.4, 114.6, 111.5, 68.1, 32.1, 29.7, 29.7, 29.5, 29.4, 
29.4, 26.1, 22.8, 14.2. ESI-MS (expected: [m+H]+= 261.21, obtained: [m+Na]+= 283.2).  
 
Scheme 6.3. Synthetic route for polymer P2, P3 and P4 
 
 
Synthesis of compound 3: To a solution of acetone mixed with K2CO3 (6.79 g, 49.13 mmol), 
NaI (7.36 g, 49.13 mmol) and 18-crown-6 (0.65 g, 2.46 mmol), 4-hydroxybenzaldehyde 
(3.00 g, 24.57 mmol) was added and stirred for 5 min. To this mixture, tert-butyl 
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bromoacetate (9.58 g, 49.13 mmol) was added and stirred while refluxing for 20 h. The 
reaction mixture was then cooled to room temperature and filtered to afford the crude 
product in acetone solution. The solvent was evaporated to dryness and purified by silica 
gel column chromatography (10-13% ethyl acetate in hexanes) to obtain 5.3 g (91% yield) 
of 3. 1H NMR (400MHz, CDCl3) δ 9.88 (s, 1H), δ 7.82-7.84 (d, J = 4.2 Hz, 2H), δ 6.97-
6.99 (d, J = 4.4 Hz, 2H), δ 4.59 (s, 2H), δ 1.47 (s, 9H). 13C NMR (100 MHz, CDCl3) δ 
190.8, 167.2, 162.8, 132.0, 130.7, 114.9, 83.0, 65.6, 28.1. ESI-MS (expected: [m+H]+= 
237.1, obtained: [m+Na]+= 259.1) 
Synthesis of compound 4: Methyltriphenylphosphonium bromide (7.94 g, 22.24 mmol) 
and potassium tert-butoxide (2.50 g, 22.24 mmol) were mixed in a round bottom flask, and 
dry THF (15 mL) was added to the mixture. The mixture was stirred under argon 
atmosphere in an ice bath for 15 min to yield the bright yellow solution. 3 (3.5 g, 14.83 
mmol) was slowly added to the mixture. The reaction mixture was further stirred for 5 h. 
After the reaction, saline and ethyl acetate were added for extraction. The combined 
organic layer was separated and washed with saline (3 times). The organic layer was 
evaporated to dryness and purified by silica gel column chromatography (3-5% ethyl 
acetate in hexanes) to afford 3.3 g (95% yield) of 4. 1H NMR (400MHz, CDCl3) δ 7.33-
7.35 (d, J = 1.0 Hz, 2H), δ 6.84-6.87 (d, J = 1.0 Hz, 2H), δ 6.63-6.68 (dd, J = 17.6, 10.9 
Hz, 1H), δ 5.60-5.64 (dd, J = 17.6, 0.9 Hz, 1H), δ 5.13-5.15 (dd, J = 10.9, 0.8 Hz,), δ 4.51 
(s, 2H), δ 1.49 (s, 9H). 13C NMR (100MHz, CDCl3) δ 168.0, δ 157.7, δ 136.2, δ 131.3, δ 
127.48, δ 114.7, δ 112.1, δ 82.4, δ 65.8, δ 28.1. ESI-MS (expected: [m+H]+= 235.1, 
obtained: [m+Na]+= 257.1) 
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Synthesis of random copolymer 5: A mixture of the compound 1 (500 mg, 1.92 mmol), 2 
(675 mg, 2.88 mmol) and N-tert-butyl-N-(2-methyl-1-phenylpropyl)-O-(1-phenylethyl) 
hydroxylamine (NMP initiator, 25 mg, 0.077 mmol) were degassed by three freeze/thaw 
cycles, sealed under argon, and heated at 120 oC under argon for 12 h. After the reaction 
cooled down to room temperature, the reaction mixture was dissolved in minimal amount 
of DCM, and precipitated 3 times in MeOH. The precipitate was collected and dried under 
vacuum to yield 988 mg (84% yield) of 5. GPC (THF): Mn= 11 K Da, Đ= 1.09. 1H NMR 
(400MHz, CDCl3) δ 6.59-6.25, 4.42, 3.85, 1.75, 1.48-1.21, 0.88. From 1H NMR, 
integration of methylene proton next to the phenol in both alkyl unit (f) and carboxylate 
unit (g) provided the molar ratio of monomers to be 4:6 (decyl/carboxylate).  
 
Synthesis of random copolymer P1: Dichloromethane (2 mL) was added to dissolve the 
dried random copolymer P1 (200 mg). Trifluoroacetic acid (0.5 mL) was added to the 
mixture and stirred for 12 h at room temperature. The reaction mixture was evaporated and 
dried under vacuum to obtain P1 (95% yield). 1H NMR (400MHz, CDCl3) δ 6.59, 4.65, 
3.90, 1.75, 1.48-1.21, 0.88. 13C NMR (100MHz, CDCl3) δ 174.2, 156.6, 154.8, 128.7, 114.2, 
68.1, 65.1, 39.9, 31.9, 29.6, 29.3, 26.1, 22.7, 14.1. GPC (DMF): Mn= 11 K Da, Đ= 1.12. 
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From 1H NMR, a sharp decrease in integration at δ 1.48 suggested the successful 
deprotection of tert-butyl group. From 1H NMR, integration of proton a and f again 
confirmed the molar ratio of monomers to be 4:6 (decyl/carboxylate) 
 
Synthesis of random copolymer 6: Carboxylate polymer P1 (100 mg, 0.22 mmol 
carboxylic acid repeat unit) and N-Hydroxysuccinimide (38 mg, 0.33 mmol) was weighed 
in a 20 mL glass vial and dissolved in 5 mL dry THF and stirred at 0 oC. N-(3-
Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC) (63 mg, 0.33 mmol) 
was added to the mixture and stirred for 4 hours. Afterwards, triethylamine (92 uL, 0.66 
mmol) and N, N-dimethylethylenediamine (29 mg, 0.33 mmol) were added dropwise to 
the reaction mixture and the solution was stirred for 24 h at room temperature. After that, 
the modified polymer was purified by dialyzing against dichloromethane/methanol using 
a membrane of MWCO: 3.5 kDa. After dialysis, the solvent was evaporated and the 
polymer was dried under vacuum for 24 h. Yield: 90%, GPC (THF) Mn: 12 K. Đ: 1.15. 1H 
NMR (400 MHz, CDCl3): δ 7.15, 6.57-6.2, 4.39, 3.84, 3.42, 2.44, 2.22, 1.74, 1.43-1.26, 
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0.88. From 1H NMR, integration of proton a and e again confirmed the molar ratio of these 
two monomers to be 4:6. 
 
Synthesis of random copolymer P2: Random copolymer 6 (80 mg, 0.16 mmol tertiary 
amine repeat unit) was weighed in a 20 mL glass vial and dissolved in 5 mL dry THF and 
stirred at 0 oC under argon protection. Methyl trifluoromethanesulfonate (56 mg, 0.33 
mmol) was added to the solution dropwise and stirred for 2 hours. Afterwards, the solvent 
was evaporated and the polymer was dried under vacuum for 24 h. Yield: 90%, GPC (THF) 
Mn: 12 K. Đ: 1.15. 1H NMR (400 MHz, acetone-d6): δ 8.24, 6.7-6.3, 4.49, 3.92, 3.77, 3.40, 
1.78, 1.48-1.26, 0.88. 13C NMR (100 MHz, CDCl3) δ 173.5, 156.6, 122.7, 53.5, 49.8, 31.9, 
29.6, 29.35, 29.33, 26.1, 22.7, 14.1. From 1H NMR, proton peak of e shifting downfield 
suggested the successful conversion of tertiary amine to quaternary ammonium. Ratios of 
two monomers were calculated based on integration of a and h.  
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Synthesis of random copolymer 7: P1 (100 mg, 0.22 mmol carboxylic acid repeat unit) and 
N-hydroxysuccinimide (38 mg, 0.33 mmol) was dissolved in 5 mL dry THF and stirred at 
0 oC. EDC (63 mg, 0.33 mmol) was added and stirred for 4 hours. Afterwards, triethylamine 
(92 uL, 0.66 mmol) was added and stirred for 30 minutes. Then a mixture of 4-(2-
aminoethyl) benzenesulfonamide (22 mg, 0.11 mmol) and N, N-dimethylethylenediamine 
(19.3 mg, 0.22 mmol) in 1 mL DMF were added dropwise and the solution was stirred for 
24 h at room temperature. After that, the modified polymer was 
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purified by dialyzing against DCM/methanol using a membrane of MWCO: 3.5 kDa. After 
dialysis, the solvent was evaporated and the polymer was dried under vacuum for 24 h. 
Yield: 93%, GPC (THF) Mn: 12 K. Đ: 1.2. 1H NMR (400 MHz, CDCl3): δ 7.82, 7.15, 6.57-
6.2, 4.56-4.2, 3.87-3.78, 3.42, 2.44, 2.22, 1.74, 1.43-1.26, 0.88. Ratios of three components 
were calculated based on integration of a, e and m. 
 
Synthesis of random copolymer P3: Random copolymer 7 (80 mg, 0.09 mmol tertiary 
amine repeat unit) was dissolved in 5 mL dry THF, 1,3-propane sultone (39 uL, 0.45 mmol) 
was added to the solution and the mixture was refluxed at 80 oC overinight. Then the 
modified polymer was purified by dialyzing against aacetone using a membrane of MWCO: 
3.5 kDa. After dialysis, the solvent was evaporated and the polymer was dried under 
vacuum for 24 h. Yield: 95%, GPC (DMF) Mn: 12 K. Đ: 1.2. 1H NMR (400 MHz, CDCl3): 
δ 7.8, 7.15, 6.57-6.2, 4.52-4.2, 4.05-3.42, 2.78, 1.98, 1.74, 1.43-1.26, 0.88. 13C NMR (100 
MHz, CDCl3) δ 181.6, 172.8, 170.4, 156.3, 128.8, 114.2, 100.5, 67.9 43.4, 39.6, 31.9, 29.6, 
29.3, 26.15, 26.13, 22.7, 14.1. Ratios of three components were calculated based on 
copolymer 7. 
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Synthesis of random copolymer P4: Random copolymer 6 (80 mg, 0.16 mmol tertiary 
amine repeat unit) was dissolved in 5 mL dry THF, 1,3-propane sultone (71 uL, 0.80 mmol) 
was added to the solution and the mixture was refluxed at 80 oC overinight. Then the 
modified polymer was purified by dialyzing against aacetone using a membrane of MWCO: 
3.5 kDa. After dialysis, the solvent was evaporated and the polymer was dried under 
vacuum for 24 h. Yield: 95%, GPC (DMF) Mn: 11 K. Đ: 1.1. 1H NMR (400 MHz, CDCl3): 
δ 8.30, 6.2-6.61, 4.64−4.29, 3.97-2.65, 1.76, 1.54-1.1, 0.87. 13C NMR (100 MHz, CDCl3) 
δ 170.7, 157.8, 129.0, 114.8, 107.9, 68.2, 50.9, 42.8, 31.9, 29.6, 29.3, 26.2, 22.7, 14.1. 
Ratios of two components were calculated based on polymer P1. 
 
Synthesis of substrate S1: Compound 8 and 9 were synthesized according to previous 
reported procedures.S2 The mixture of compound 8 (1.0 eq), compound 9 (2 eq), 
CuSO4.5H2O (0.5 equiv.) and sodium ascorbate (0.5 eq.) in MeOH/H2O (1:1) solvent 
mixture was heated at 50 oC for 24 h. The reaction progress was monitored by TLC. After 
completion of the reaction, the reaction mixture was partitioned between ethyl acetate and 
saturated aqueous NH4Cl solution. The aqueous layer was extracted twice with ethyl 
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acetate and the combined organic layer was dried over Na2SO4 and evaporated to dryness. 
The crude product was purified by silica gel column chromatography. Yield: 93%, 1H 
NMR (400 MHz, CDCl3) δ 7.61 (s, 1H), δ 7.53 (d, J = 4.4 Hz, 1H), δ 6.95 (m, 2H), δ 6.61-
6.52 (m, 2H), δ 6.18 (s, 1H), δ 5.80 (s, 2H), δ 5.15 (s, 2H), 4.32 (t, J = 3.6 Hz, 2H), δ 4.12 
(t, J = 4.8 Hz, 2H), δ 3.85 (t, J = 4.6 Hz, 2H), δ 3.75-3.62 (m, 26H), δ 3.55 (m, 2H), δ 3.36 
(s, 3H), δ 3.10 (s, 3H), δ 2.95 (s, 3H), δ 2.4 (m, 4H), δ 1.92 (m, 2H), δ 1.65 (m, 4H), δ 1.35 
(m, 2H); 13C NMR (100 MHz, CDCl3) δ 171.9, 160.9, 160.0, 159.4, 159.2, 154.9, 152.3, 
138.4, 125.9, 115.2, 113.2, 113.0, 106.2, 106.0, 103.4, 84.8, 71.9, 70.8, 70.6, 70.58, 70.50, 
69.6, 59.1, 40.1, 35.4, 33.7, 29.3, 26.2, 23.9, 18.7. HR-ESI-MS (calculated: [m+H]+= 
931.45, obtained: [m+Na]+= 953.3553). 
 
 
 
  
  
 
136 
6.5 References 
1. Yang, N. J.; Hinner, M. J. Methods Mol. Biol. 2015, 1266, 29–53. 
2. Huang, J.; Lein, M.; Gunderson, C.; Holden, M. A. J. Am. Chem. Soc. 2011, 133, 
15818–15821. 
3. Orozco, J.; Cortés, A.; Cheng, G.; Sattayasamitsathit, S.; Gao, W.; Feng, X.; Shen, Y.; 
Wang, J. J. Am. Chem. Soc. 2013, 135, 5336–5339. 
4. Denzer, K.; Kleijmeer, M. J.; Heijnen, H. F.; Stoorvogel, W.; Geuze, H. J. J. Cell Sci. 
2000, 113, 3365–3374. 
5. Skog, J.; Wurdinger, T.; Van Rijn, S.; Meijer, D.; Sena-Esteves, M.; Curry Jr, W. T.; 
Carter, R. S.; Krichevsky, A. M.; Breakefield, X. O. Nat. Cell Biol. 2008, 10, 1470. 
6. Yu, G.; Jie, K.; Huang, F. Chem. Rev. 2015, 115, 7240–7303.  
7. Ma, X. Zhao, Y. Chem. Rev. 2015, 115, 7794-7839. 
8. Cui, H.; Xu, B. Chem. Soc. Rev. 2017, 46, 6430–6432. 
9. Oldfield, C. Biotechnol. Genet. Eng. Rev. 1994, 12, 255-327. 
10. Leser, M. E., Mrkoci, K. & Luisi, P. L. Biotechnol. Bioeng. 1993, 41, 489-492. 
11. Nicot, C.; Waks, M. Biotechnol. Genet. Eng. Rev. 1996, 13, 267-314. 
12. Valdez, D.; Le Huerou, J. Y.; Gindre, M.; Urbach, W.; Waks, M. Biophys. J. 2001, 80, 
2751-2760. 
13.  Du, X., Song, N., Yang, Y.W., Wu, G., Ma, J. and Gao, H.. Polym. Chem. 2014, 5, 
5300–5309. 
14. Cöklen, K. E. & Hatton, T. A. Biotechnol. Prog. 1985, 1, 69–74. 
15. Colletier, J.-P.; Chaize, B.; Winterhalter, M.; Fournier, D. BMC Biotechnol. 2002, 2, 9. 
16. Lawrence, M. S.; Phillips, K. J.; Liu, D. R. J. Am. Chem. Soc. 2007, 129, 10110–10112. 
  
 
137 
17. Alterio, V.; Di Fiore, A.; D’Ambrosio, K.; Supuran, C. T.; De Simone, G. Chem. Rev. 
2012, 112, 4421–4468. 
18. Whitcombe, M. J.; Chianella, I.; Larcombe, L.; Piletsky, S. A.; Noble, J.; Porter, R.; 
Horgan, A. Chem. Soc. Rev. 2011, 40, 1547–1571. 
19. Rodthongkum, N.; Ramireddy, R.; Thayumanavan, S.; Richard, W. V. Analyst 2012, 
137, 1024–1030. 
20. Santra, S.; Zhang, P.; Wang, K.; Tapec, R.; Tan, W. Anal. Chem. 2001, 73, 4988–4993. 
21. Wang, M.; Gao, J.; Zhao, B.; Thayumanavan, S. Vachet, R.W. Analyst ,2019 , 144, 
6321-6326. 
22. Serrano, M. A. C.; Gao, J.; Kelly, K. A.; Thayumanavan, S.; Vachet, R. W. ACS Appl. 
Mater. Interfaces 2018, 10, 40443–40451. 
23. Zhao, B.; Serrano, M. A. C.; Gao, J.; Zhuang, J.; Vachet, R. W.; Thayumanavan, S. 
Polym. Chem. 2018, 9, 1066-1071. 
24. Nam, J.-M.; Thaxton, C. S.; Mirkin, C. A. Science. 2003, 301, 1884–1886. 
25. Zhang, H.; Piacham, T.; Drew, M.; Patek, M.; Mosbach, K.; Ye, L. J. Am. Chem. Soc. 
2006, 128, 4178–4179. 
26. Vriezema, D. M.; Comellas Aragonès, M.; Elemans, J. A. A. W.; Cornelissen, J. J. L. 
M.; Rowan, A. E.; Nolte, R. J. M. Chem. Rev. 2005, 105, 1445–1490. 
27. Bruns, N.; Tiller, J. C. Nano Lett. 2005, 5, 45–48. 
28. Grzelakowski, M.; Onaca, O.; Rigler, P.; Kumar, M.; Meier, W. Small 2009, 5, 2545–
2548. 
29. Broz, P.; Driamov, S.; Ziegler, J.; Ben-Haim, N.; Marsch, S.; Meier, W.; Hunziker, P. 
Nano Lett. 2006, 6, 2349–2353. 
  
  
 
138 
 
 CHAPTER 7 
 ENZYME NANOREACTOR FOR CATALYSIS IN APOLAR SOLVENT 
7.1 Introduction 
  Despite many decades of research to match the catalytic fidelity of nature’s 
macromolecules, enzymes still remain the hallmark of excellence for activity, selectivity, 
and turnover numbers.1,2 Nature had billion years of evolutionary pressure as the driving 
force to arrive at these efficient catalysts. Achieving such fidelity, using synthetic 
molecules, on a reasonable human time scale is difficult.3–7 Therefore, it is useful to capture 
the essence of biological catalysts themselves in abiological processes. This goal is 
complicated by the fact that practical utility of enzymes is quite limited in most abiological 
processes, because these catalysts are evolved to only operate in their native environment.8–
11 Endowing proteins with the ability to operate in non-native environments is clearly a 
challenge, which has been recognized for several decades.12–14 A promising solution to this 
challenge would involve the ability to encapsulate proteins in a compatible local nano-
environment, although the global environment of the reaction media might be incompatible 
with the protein.15–18 Although this is easy to imagine, implementation of such a possibility 
is cumbersome, because this requires proteins to be transported across the incompatible 
solvent interface. 
  Reverse micelles or water-in-oil microemulsions, stabilized by amphiphilic molecules, 
can form the basis for distributing enzymes in apolar organic solvents.19–24 In this approach, 
the enzymes can be directly encapsulated inside without the need of any functional group 
modification. With the presence of surfactants at the interface of water and organic solvents, 
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enzymes are protected against potential denaturation by the bulk organic solvents. This 
scenario allows for organic substrate molecules to be conveniently distributed in the bulk 
solvent. We have shown a simple polymeric platform that selectively transports water-
soluble proteins from an aqueous phase to the water-pool of a reverse micelle in an apolar 
organic phase based on complementary electrostatic interactions or specific ligand-protein 
binding interactions.25 Such a capability provides a great opportunity for performing and 
modulating enzymatic catalysts in organic solvents. Controlling substrate accessibility to 
the core of the nanoreactor can expand the system to function in a more complex 
environment, where a mixture of substrates is present. In this chapter, we will build enzyme 
nanoreactors for catalysis in apolar solvent, and then introduce crosslinks in the molecular 
assemblies to control substrate permeability into the assembly to engineer unnatural 
selectivity in enzymes that are known to be inherently promiscuous in substrate selectivity 
(Figure 7.1).  
 
Figure 7.1. Schematic representation of enzyme nanoreactor in organic phase and introduce 
unnatural substrate selectivity to the enzymes for catalysis in apolar solvent. 
 
7.2 Results and discussion 
7.2.1 Molecular design and synthesis 
  We are interested in engineering the reverse micelle scaffold to introduce new substrate 
selectivity in enzymes, which are known to be inherently promiscuous. We hypothesize 
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that crosslinking the reverse micelles in the organic phase would affect the substrate 
permeability into this aggregate, which should introduce size-based selectivity. For this 
purpose, we propose a polymer design, achieved using nitroxide-mediated polymerization, 
comprises of 50% p-decyloxystyrene as the hydrophobic monomer and 50% of N-
methylpyridyldisulfide-styrene as the hydrophilic monomer. The hydrophilic side chain 
functionalities also can be readily crosslinked in presence of dithiolthreitol (DTT). The 
polymer was prepared following scheme 7.1. 
Scheme 7.1 Synthesis route for target polymer 
 
7.2.2 Reverse micelle preparation and characterization 
 
Figure 7.2. a) DLS profile of target polymer in DCM at 1 mg/mL; b) TEM images of 
reverse micelle solutions. 
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  We firstly tested whether this polymer would self-assemble in apolar solvent. By 
distributing it in different organic solvents such as toluene, dichloromethane, chloroform 
and ethylacetate at a concentration of 1 mg/mL (2 eq. water per charged group), we have 
observed aggregate formation in DCM and chloroform. Assemblies with a fairly 
homogeneous size distribution of 500 nm was found for designed polymer, as discerned by 
both dynamic light scattering (DLS) (Figure 7.2a) and transmission electron microscopy 
(TEM) (Figure 7.2b). The water molecules are added here to provide a ‘water pool’ for the 
reverse micelles, which is quite critical for the enzyme entrapment and retainment of 
enzyme activity in the following experiments. Therefore, we have tried to vary the water 
content of the reverse micelle assemblies from 0.5 uL to 5 uL per mL reverse micelle 
solution. We have figured out that if water is more than 2 uL per mL reverse micelle 
solution, the assemblies were no longer stable because we didn’t see a peak from DLS.  
Only when water addition is lower than 2 uL/mL could we see peaks from DLS. Also, with 
the increasing amount of water, the size of reverse micelles also increased (Figure 7.3). 
  
Figure 7.3. DLS profiles for reverse micelles with varied amount of water added. 
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  Next, we are curious to see whether we could crosslink the reverse micelles and control 
the crosslinking density. In addition to increasing thermodynamic stability to the reverse 
micelle assemblies, this process should also offer selective permeability of substrate 
molecules. For this purpose, we added different amount of DTT to induce the disulfide 
crosslinking. As shown in Figure 7.4, we firstly quantified the maximum amount of the 
PDS group in 1 mg/ml polymer solution based on the absorbance of cleaved PDS at 350 
nm. Then varied amount of DTT from 0.1 eq. to 0.3 eq. of PDS group was added to the 
reverse micelle solution to get desired crosslinking density (Figure 7.4). 
 
Figure 7.4 Crosslinking of reverse micelles with varied amount of DTT 
7.2.3 Enzyme encapsulation and quantification 
  We envisaged that our reverse micelles would bind to complementarily charged proteins 
in the aqueous phase and ferry them over to the organic phase and remain active based on 
our previous findings. To test this possibility, we used GFP as the model protein because 
we can easily monitor the encapsulation and speculate their structural integrity using 
fluorescence. As shown in Figure 7.5a, with increased polymer concentration from 0.25 
0
0.2
0.4
0.6
0.8
1
330 350 370 390 410 430 450 470
Wavelength (nm)
Ab
so
rb
an
ce
60% xlinking
50% xlinking
40% xlinking
20% xlinking
  
 
143 
mg/mL to 1 mg/mL, we observed increased encapsulation in organic phase, suggested from 
the increase in fluorescence signal of GFP. 
  We were then excited to test this system with an enzymatic protein, porcine liver esterase 
(plE), which would be the model enzyme to build nanoreactor due to its catalytic efficiency 
in a variety of ester substrates. To monitor and quantify the enzyme encapsulation by 
reverse micelles, we labeled plE with a fluorescent dye, Cy3. Herein we have tried two 
different approaches for enzyme encapsulation: 1) liquid-liquid extraction between reverse 
micelle in DCM and enzyme solution in PBS buffer; 2) directly add 1uL of plE aqueous 
solution into the organic phase and sonicate. We found that two approaches offered same 
loading capacity based on the same polymer concentration. The loading capacity for 
1mg/mL polymer was found to be 2.75 nM.   
 
Figure 7.5. a) GFP encapsulation by reverse micelles with varied concentration; b) Cy3 
labeled plE encapsulation in reverse micelles through extraction approach (blue) or 
sonication approach (orange). 
 
7.3 Summary and future directions 
  In this chapter, we have investigated the use of amphiphilic polymer based reverse 
micelles to transport enzymes across an immiscible solvent interface in order to perform 
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enzymatic catalysis in organic solvents. Using random cationic amphiphilic polymer, we 
have shown the preparation of reverse micelles, enzyme encapsulation in apolar solvent 
and controlled crosslinking density of these nanoassemblies. We found that the micelle size 
can be tuned by the amount of water added. Crosslinking of reverse micelles from the 
hydrophilic core can be achieved using disulfide chemistry but the DTT might affect the 
protein activity in the following studies. Future work will need to use different crosslinking 
chemistry to minimize the implications in the encapsulated enzyme. Also, studying the 
enzyme catalysis over a range of different substrates will be done to figure out whether 
there can be a threshold for the molecules to diffuse into the reactor. 
7.4 Experimental procedures 
7.4.1 General methods 
All reagents were commercially available and used as received unless stated otherwise. 1H-
NMR spectra were recorded on a 400 MHz or a 500 MHz NMR spectrometer using residual 
proton resonance of the solvents as internal standard. Chemical shifts are reported in parts 
per million (ppm). Mass spectra were obtained by a Bruker AmaZon quadrupole ion trap 
mass spectrometer coupled with electrospray ionization source. Gel permeation 
chromatography (GPC) was used to estimate the molecular weight of polymers using 
THF/DMF as eluent and 1 μL of toluene was added as the internal reference. Polystyrene 
standards were used for calibration and data analysis.  
Dynamic Light Scattering (DLS): For the DLS measurements, the polymers were dissolved 
in toluene/dichromethane/chloroform, and two equivalent of water per hydrophilic unit 
was added to form the water pool inside the reverse micelles. The samples were sonicated 
until clear solutions were formed. DLS measurements were carried out in a quartz cuvette 
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at room temperature. The sizes of each solution were recorded overtime by a Malvern 
Nanozetasizer ZS90.  
Transmission Electron Microscope (TEM): The same sample for DLS measurement was 
dropped onto carbon-coated copper grid. The grid was dried by slow evaporation in air 
overnight. Images were recorded on a JEOL-2000FX electron microscopy operated at 
200 kV and at a nominal magnification of 5000X. At least 10 locations on the TEM grid 
were examined. The assembly diameter was calculated using ImageJ software. 
Protein encapsulation by reverse micelles:  600 uL of a DCM solution of polymers (1 
mg/mL) with 200 uL of enzyme in 10 mM PBS buffer at pH 7.4. The mixture is vortexed 
for 30 min and centrifuged at 10,000 rpm for 1 h to separate the organic and aqueous layers. 
The organic phase and aqueous phase are then separated for analysis.  
Evaluation of PlE activity in reverse micelles: First, the amount of plE that got transported 
into the organic phase was calculated based on the SDS-PAGE or BCA assay. The organic 
phase containing plE was then equilibrated with an aqueous phase of substrate S1 (100 µM) 
for 30 minutes. After centrifugation for 30 minutes, the fluorescence of aqueous phase was 
measured over time. The control experiments with the same amount of plE were performed 
in aqueous phase. 
7.4.2 Synthesis 
 
Synthesis of molecule 2: Methyltriphenylphosphonium bromide (7.94 g, 22.24 mmol) and 
potassium tert-butoxide (2.50 g, 22.24 mmol) were mixed in a round bottom flask, and dry 
THF (30 mL) was added to the mixture. The mixture was stirred under argon atmosphere 
in an ice bath for 15 min to yield the bright yellow solution. Molecule 1 (2.2 g, 14.83 mmol) 
was slowly added to the mixture. The reaction mixture was further stirred overnight. After 
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the reaction, THF was evaporated, saline and ethyl acetate were then added for extraction. 
The organic layer was washed with saline (3 times) and then evaporated to dryness and 
purified by silica gel column chromatography (3-5% ethyl acetate in hexanes) to afford 1.3 
g (65% yield) of 2. 1H NMR (400MHz, CDCl3) δ 7.97-7.99 (d, J = 8.0 Hz, 2H), δ 7.46-
7.44 (d, J =8 Hz, 2H), δ 6.78-6.71 (dd, J = 11.2, 11.2 Hz,), δ 5.88-5.84 (d, J =16 Hz, 1H), 
δ 5.40-5.37 (d, J =12 Hz, 1H). ESI-MS (expected: [m+H]+= 149.05, obtained: [m+Na]+= 
171.1)  
Scheme 7.2 Synthesis route for monomers and target polymer 
 
 
Synthesis of molecule 3: Molecule 2 (1.3 g, 8.7 mmol), SOCl2 (1.2g, 10.4 mmol) and THF 
(20 mL) were kept under reflux for overnight. The mixture was then evaporated to dryness 
and redissolved in fresh and dry THF (20 mL). 2-Hydroxyethylpyridyldisulfide (1.63g, 8.7 
mmol) and triethylamine (1.77g, 17.4 mmol) with 5mL THF was then added to this solution 
and stirred at room temperature for 12 hours. Solvent was evaporated and the residue was 
further purified by silica gel column chromatography (3-5% ethyl acetate in hexanes) to 
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afford 2.2 g (83% yield) of 3. 1H NMR (400 MHz, CDCl3) δ 8.45-8.44 (d, J = 4.0 Hz, 1H) 
7.97-7.99 (d, J = 8.0 Hz, 2H), δ 7.70-7.68 (d, J = 8.0 Hz, 1H), δ 7.58-7.53 (m, 1H), δ 7.46-
7.44 (d, J =8 Hz, 2H), δ 7.07-7.04 (m, 1H), δ 6.78-6.71 (dd, J = 11.2, 11.2 Hz,), δ 5.88-
5.84 (d, J =16 Hz, 1H), δ 5.40-5.37 (d, J =12 Hz, 1H), δ 4.56 (t, 2H), δ 3.18 (t, 2H). ESI-
MS (expected: [m+H]+= 318.05, obtained: [m+Na]+= 340.13) 
Synthesis of polymer P0: A mixture of the compound 3 (610 mg, 1.92 mmol), 4 (499 mg, 
1.92 mmol) and N-tert-butyl-N-(2-methyl-1-phenylpropyl)-O-(1-phenylethyl)hydroxyl 
amine (NMP initiator, 25 mg, 0.077 mmol) were degassed by three freeze/thaw cycles, 
sealed under argon and heated at 120 oC for 10 h. After the reaction cooled down to room 
temperature, the reaction mixture was dissolved in minimal amount of DCM and 
precipitated 3 times in MeOH. The precipitate was collected and dried under vacuum to 
yield 1045 mg (95% yield) of 5. GPC (THF): Mn= 14.5 K Da, Đ= 1.09. 1H NMR (400 
MHz, CDCl3) δ 8.43, 7.69, 7.55, 7.04, 6.56, 4.54, 3.86, 3.17, 1.74-1.21, 0.88. From 1H 
NMR, integration of peak at δ 4.54 and peak at δ 3.86 provided the molar ratio of monomers 
to be 1:1 (decyl/PDS).  
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Synthesis of polymer P1: Random copolymer P0 (200 mg, 0.35 mmol PDS repeat unit) 
was weighed in a 20 mL glass vial and dissolved in 5 mL dry dichoromethane and stirred 
at 0 oC under argon protection. Methyl trifluoromethanesulfonate (118 mg, 0.7 mmol) was 
added to the solution dropwise and stirred for 2 hours. Afterwards, the solvent was 
evaporated, the polymer was dried under vacuum for 24 h. Yield: 90%, GPC (THF) Mn: 
15 K. Đ: 1.15. 1H NMR (400 MHz, acetone-d6): δ 9.03, 8.77, 8.54, 7.93, 7.76, 6.71, 4.67, 
4.66, 3.94, 3.52, 3.40, 1.78-1.26, 0.88. From 1H NMR, proton peak of δ 4.46 suggested the 
successful conversion of tertiary amine to quaternary ammonium.  
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CHAPTER 8 
 SUMMARY AND FUTURE DIRECTIONS 
8.1 Summary of the dissertation 
Through the use of modern synthetic organic chemistry, we have  built interesting, novel 
and smart Nanoassemblies with tunable responses and potential applications such as 
sensing, diagnostics and drug delivery. We have synthesized a variety of amphiphiles to 
understand the structural factors that program molecules to self-assemble into functional 
materials. Furthermore,  by addressing the design challenge to prepare smart materials with 
desired functionalities, controlled molecular weight and the ability to respond to a broad 
range of stimuli, we have developed different applications based on these materials.  
The primary challenge for design of novel stimuli-responsive materials concerns stimulus 
and response. In chapter 2, taking different stimulus as inputs and response as outputs, I 
successfully achieved logic control over the designed materials. Notably, a combination of 
an intrinsic trigger and an extrinsic trigger was introduced to this system for the first time. 
A photocaged ligand activation method was designed that nanoassembly would 
disassemble only to the concurrent presence of two inputs (AND gate). Similarly, 
molecular designs for OR gate and NOT gate were also developed and demonstrated. This 
set of materials offer the possibility of substantially increasing specificity in responses, 
which could find use in many applications, including drug delivery and diagnostics. 
Enzyme as a stimulus to trigger the response of nanomaterials is an exciting finding from 
our group and has shown great potential for developing rapid response materials for sensing. 
In chapter 3, rrom the chemistry perspective, I have a strong desire to dig the structural 
factors that tailor the molecules to self-assemble into enzyme responsive materials. By 
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synthesizing two series of 12 new oligomers with varied structures, I systematically 
investigated how molecular weight and hydrophilic-hydrophobic balance affects the 
materials’ response towards enzyme. The fundamental insights generated from these 
findings are impacting the new materials design in our group and will also benefit areas of 
enzyme-sensitive materials.     
In chapter 4, I designed a self-immolative nanogel platform based on block-copolymers, 
which aims to minimize the implications associated with currently reported systems such 
as stability loss and limited efficiency for post-modification. The new material design 
involves simple synthesis and accessible reactive group present on the surface, which can 
be easily functionalized with ligand functionalities. The easy preparation and capabilities 
for post-modification provide great potential to be used as delivery vehicles.   
When translating nanoparticle-based biomedical imaging and therapy, one big obstacle is 
the poor selectivity of these materials in vivo due to off-target localization. To address this 
issue, In chapter 5 we come up with a simple material design that are available to mask cell 
interactive functionalities on nanogel during circulation and then restore nanogel-cell 
interaction by revealing the presence of these surface functionalities at a target site.  These 
nanogels with triggerable variational properties can function as imaging agents, my success 
on this project will push our work on step closer to industrial applications. 
Transporting molecules across incompatible interfaces is a significant challenge, especially 
for globular proteins with large hydrophilic surfaces. If we could transport enzymes into 
an organic phase without disrupting the structure and functions of these enzymes, it would 
raise up a broad range of applications such as catalysis and sensing. To combat this problem, 
I developed a novel and simple supramolecular approach in chapter 6, with which we were 
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gratifying to find that not only the proteins can be easily shuttled from aqueous phase to 
organic phase, their structures and functions are well maintained. Another achievement is 
that specific protein from mixtures can be selectively extracted by introducing ligand into 
the materials. These exciting findings from my project open up new possibilities for 
application of supramolecular assemblies in sensing, diagnostics and catalysis. 
Following the findings in chapter 6,  we use specifically engineered interactions between 
a polymer assembly in the apolar organic phase and a protein as the driving force to 
transport the protein that was originally present in the aqueous phase in chapter 7. By 
crosslinking the reverse micelles in the organic phase, we could introduce new size-based  
selectivity in enzymes. Controlling substrate accessibility to the core of the nanoreactor 
can expand the system to function in a more complex environment, where a mixture of 
substrates is present. 
8.2 Future directions 
8.2.1 Unnatural silectivity in enzyme nanoreactor 
Controlling substrate accessibility to the core of the nanoreactor can expand the system to 
function in a more complex environment, where a mixture of substrates is present. With 
this reverse micelle scaffold, we can introduce new substrate selectivity in enzymes, which 
are known to be inherently promiscuous. We hypothesize that crosslinking the reverse 
micelles in the organic phase would affect the substrate permeability into this aggregate, 
which should introduce size-based selectivity. We will test this permeability using a series 
of substrate molecules that contain the same enzyme-sensitive functional group, but with 
systematic variations in molecular weights of the substrate molecules (Scheme 8.1a).  
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Scheme 8.1 Structures of substrates with varied molecular weight for enzyme nanoreactors 
 
To further investigate the impact of the crosslinking-based selectivity in these assemblies, 
we will also test the catalytic function using amphiphilic substrates to delineate the effect 
of hydrophobicity that could affect the inherent accessibility to the interior of nanoreactors.  
The proposed structures are shown in Scheme 8.1 b. 
 It is also reasonable to expect that crosslinking density of the reverse micelles would alter 
the substrate selectivity. To investigate this possibility, we will systematically vary the 
extent of DTT crosslinker addition and assess change in substrate selectivities in these 
assemblies.  
 Unifying the lessons from these Aims will provide robust design guidelines for the next 
generation of enzyme nanoreactors for performing biocatalysis in apolar solvent, with 
capabilities that do not exist at this time. In addition to bringing the high catalytic fidelity 
of nature’s catalysts as an enabler in organic synthesis, these design guidelines will also 
open up new possibilities for versatile applications such as on-demand release, point-of-
care catalysis, sensing and drug delivery. 
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8.2.2 Switchable catalytic reactions in the reverse micelles  
Triggerable materials have been extensively explored for various applications such as 
controlled release and sensing, because their response can be turned ‘on’ by certain 
stimulus.1-6 Inspired by the opportunities such triggerable materials offer, we are interested 
in identifying opportunities to effectively regulate reaction processes and behaviors with 
external stimuli by simply controlling the timepoint to switch the nanoreactors ‘on’ and 
‘off’. For this purpose, we design a light triggerable enzyme nanoreactor that can perform 
on-demand catalytic function in apolar organic solvents. Light as the catalysis-controlling 
agent is particularly appealing, since it offers a non-contact, extrinsic control and can be 
delivered instantaneously to the whole system without any diffusion limitations that are 
inherent to chemical and thermal deliveries. Additionally, its operational convenience and 
temporal control over the light irradiation time and intensity can improve the practical 
potential of the light-responsive catalytic system enormously.  
 
Figure 8.1 (a) Schematic representation shows triggerable switch for turn ‘on’ and ‘off’ of 
the nanoreactor.  (b) molecular design and reversible crosslinking chemistry reaction using 
coumarin. 
Crosslink (UV 365 nm)
Organic phase 
+
(a)
(b)
Decrosslink (UV 280 nm)
Nanoreactor “ON” Nanoreactor “OFF”
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Here we choose coumarin as the hydrophobic moiety, which is also crosslinkable. 
Coumarins can undergo a 2+2 photo-dimerization upon irradiations at l > 300 nm, whereas 
the reverse photo-scission reaction occurs under irradiation at l < 300 nm.7-8 We will 
choose the crosslink densities, using the lessons learnt from the sub-Aims above, such that 
these assemblies do not allow substrate molecules to enter the lumen of the assembly when 
crosslinked. In this scenario, we can indeed regulate the accessibility of certain substrate 
to enzyme and thus control the reaction by crosslinking or decrosslinking the reverse 
micelle systems (Figure 8.1).  
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